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The Role of Src Homology 2 Domain Containing Inositol-5’-Phosphatase 1
(SHIP) in Hematopoietic Cells
Caroline Desponts
ABSTRACT
The principal isoform of Src homology (SH) 2-domain containing 5’ inositol
phosphatase protein 1 (SHIP) is a 145kDa protein primarily expressed by cells of
the hematopoietic compartment. The enzymatic activity of SHIP is responsible
for hydrolyzing the 5’ phosphate of phosphatidylinositol-3,4,5-trisphosphate
(PI(3,4,5)P3), and thereby preventing the recruitment of pleckstrin homology
domain containing effector proteins. Furthermore, SHIP contains protein-protein
interaction domains, such as an SH2 domain, two NPXY and several proline-rich
motifs. All of these different domains endow SHIP with the capacity to impact
signaling pathways important for proliferation, survival, differentiation and
activation. Therefore, we hypothesized that SHIP-deficiency could result in the
loss of hematopoietic cell homeostasis and function

To this verify this hypothesis, we first studied the effect of SHIP ablation
on hematopoietic stem cell (HSC) proliferation, survival, function and homing.
Most interestingly we observed that SHIP impacts HSC homeostasis and their
xii

ability to home appropriately to the bone marrow. Then, since SHIP was shown
to be activated after engagement of the c-mpl receptor by its ligand,
thrombopoietin, we studied the impact of SHIP deletion on the function of
megakaryocytes, the major target cell of that cytokine. We found that SHIP is
also important for homeostasis of the megakaryocyte compartment. Thirdly, we
studied the role of SHIP in natural killer (NK) cells biology. We observed that F4
generation SHIP-/- mice have increased NK cells in their spleen and that these
cells exhibit a disrupted receptor repertoire.

We verified the hypothesis that

SHIP helps shape the receptor repertoire of NK cells, mainly through regulation
of cell survival and proliferation. Also included, is a study on the role of a SHIP
isoform lacking the SH2-domain, called stem cell-SHIP (s-SHIP) in the biology of
embryonic stem (ES) cells. To date, this isoform is expressed by stem/progenitor
cells and not by normal differentiated cells.

Due to its specific expression

pattern, s-SHIP has the potential to have an important role in stem cell biology.

xiii

INTRODUCTION ON SH2 DOMAIN CONTAINING 5’ INOSITOL
PHOSPHATASE 1 (SHIP)

SHIP stands for Src homology (SH) 2 domain containing 5’ inositol
phosphatase 1 and is a protein primarily expressed by cells of the hematopoietic
compartment.1-4 In 1996, five independent groups cloned murine SHIP using its
ability to bind; 1) the SH3 domain of growth factor receptor-bound protein 2
(Grb2),2 2-3) the protein-tyrosine binding domain (PTB) of SH2-containing
sequence protein (Shc) (also called SH and collagen gene or SH2-containing
oncogene src homology protein),3,4 4) the FcγRIIB,5 and 5) by gene trap assay.6

SHIP is known to hydrolyze the 5’phosphate of phosphatidylinositol-3,4,5phosphate (PI(3,4,5)P3) in vivo and inositol-1,3,4,5–tetrakisphosphate (I(1,3,4,5)P4) in
vitro,2,4 two inositides phosphates important for cell signaling (Figure 1).7-10 Since
SHIP appears to require the presence of a phosphate on the 3’ position to exert
its effect, it was proposed that it opposes the activity of phosphatidyl inositol 3'
kinase (PI3K), and by doing so, regulates several cellular signaling pathways
important for proliferation, differentiation, apoptosis and migration.

1

SHIP was first observed as a 145kDa protein that becomes tyrosinephosphorylated after stimulation of hematopoietic human DA-ER and MO7-ER
cell lines with erythropoietin (Epo).11 In this particular model, stimulation of these
cells with Epo resulted in SHIP tyrosine-phosphorylation and association with
Shc.11

Shc being implicated in several mitogenic signaling transduction

pathways,12 it became essential to determine the role of SHIP in hematopoietic
cell function.

It was then determined that stimulation of several receptors

resulted in SHIP tyrosine-phosphorylation and/or SHIP association with other
signaling molecules such as SH2-containing tyrosine phosphatase (Shp-2),13 and
Grb2.14,15 SHIP becomes activated after engagement of cytokines, chemokine
and immunological receptors. The cytokines that have been identify to stimulate
SHIP consist of interleukin (IL)-3,13,16-18 IL-4,19,20 macrophage colony stimulating
factor (M-CSF or c-FMS),21 granulocyte-macrophage-CSF (GM-CSF),16,18
granulocyte-CSF(G-CSF),22,23

Stem

Cell

Factor

(c-KitL

or

SCF),1,16

thrombopoietin (TPO),24,25 Fms-like tyrosine kinase 3 ligand (Flt3L).26 The major
chemokine known to induce SHIP recruitment is stromal cell derived factor1/CXCL12 (SDF-1) which binds to the CXCR4 receptors on multiple
hematopoietic cells.27,28 The immunological receptors known to recruit SHIP are
the Fc receptor,5,29,30 the T cell receptor,31 and B-cell-receptor Ig-α and Ig-β
chains.32-34

Once SHIP is activated or recruited by these receptors, it can

dampen the levels of PI(3,4,5)P3, phosphorylation of Protein Kinase B (Akt or
PKB), accumulation of intracellular calcium, the formation of the protein complex,
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composed of Shc, Grb2, and Son of Sevenless (SOS), and by doing so, SHIP
negatively regulates the activation of the mitogen-activated protein kinase (MAPK
or Erk) pathway (Figure 1). For example, SHIP impacts pathways downstream of
G-CSF receptors that tightly regulate proliferation and survival of neutrophils.22,23
The cytoplasmic tail of the G-CSF receptor contains a region that is responsible
for recruiting PI3K and stimulating proliferation and survival signaling pathways.22
On the other hand, this same receptor has another region on its cytoplasmic tail
that can recruit the SHIP/Shc complex, this region is associated with negative
regulation of proliferative signaling.22 This demonstrates the great balancing act
in which these molecules are involved.

3

Figure 1. Signaling pathways influenced by SHIP. Engagement of receptor by its ligand
leads to recruitment of SHIP with can impact different signaling pathway. 1) SHIP can
prevent the Grb2/SOS from binding to Shc, thus preventing the activation of RAS and
the downstream MAPK pathway. 2) Alternatively, SHIP can hydrolyze the 5’ phosphate
of PI(3,4,5)P3 generating PI(4,5)P2. This prevents the recruitment of pleckstrin homology
(PH) containing protein to the membrane and their activation. In this manner, SHIP
prevents activation of Bruton’s tyrosine kinase (Btk), which is responsible for
phospholipase Cγ (PLCγ) activation, leading calcium entry and MAPK activation. SHIP
also dampens the recruitment and activation of Akt, which leads to phosphorylation of
proteins in the Bcl family, such as BAD, Bcl-2, BclXL, preventing apoptosis.
Furthermore Akt can phosphorylate Forkhead (FH) and prevent its translocation to the
nucleus.35,36 Consequently, FH is prevented from inducing transcription of cell death
related genes such as Fas ligand (FasL).35

4

SHIP Structure and Cell Signaling

The SHIP protein sequence contains several interaction domains including
an SH2 domain, a 5’inositol phosphatase, several proline-rich domain, and two
NPXY motifs (Figure 2A). Full length SHIP is a 145kDa protein,11 which has
several isoforms that have different molecular weight including an 130kDa or
135kDa isoform in human and murine cells, respectively, and an 110kDa isoform
found in both human and murine cells (Figure 2).4,37 All of these isoforms appear
to have lost a specific protein domain when compared to full length SHIP, which
could lead to having a different function in the cell.

SH2 Domain

The SH2 domain of SHIP, stands for Src homology domain 2, a structure
that has the potential to bind to phosphotyrosine.38,39 Using this domain SHIP
can bind to phosphorylated immuno-receptor tyrosine based activation or
inhibition motifs (ITAMs or ITIMs)5,40 present in the cytoplasmic tail of several
receptors, such as FcγRIIB (ITIM) on B cells,5,41 Ly49A and C receptors on
natural killer (NK) cells,42,43 and FcRεI (ITAM) on mast cells.40,44

The SH2

domain of SHIP was also shown to interact with the Src kinase Lyn,45 which can
phosphorylate SHIP.46 This stabilizes SHIP near the membrane and enhances
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its capacity to regulate the Akt signaling pathway.45 It is important to note that
location more than phosphorylation contributes to SHIP phosphatase activity.46
Furthermore, it was shown that the SH2 domain of SHIP interacts with tyrosinephosphorylated Shp-2.13,17 Since a SHIP mutant, with a deleted SH2 domain,
can not be phosphorylated or bind to Shc nor Shp-2 after stimulation with IL-3, it
was suggested that this domain is crucial for SHIP function.13,47,48 Consistent
with this observation, we found that a SHIP isoform lacking the SH2 domain
called stem cell-SHIP (s-SHIP) (Figure 2) can not get phosphorylated and is
unable to associate with Shc after stimulation of embryonic stem (ES) cells with
leukemia inhibitory factor (LIF).49 The SH2 domain of full-length SHIP appears to
compete with Grb2 for interaction with the same phosphorylated tyrosine on
Shc.1 Interaction of Shc with Grb2 would lead to the recruitment of a protein
complex including SOS, which catalyzes the exchange of GDP to GTP on RAS,
resulting in the activation of the MAPK/Erk pathway.1

Thus, SHIP prevents

formation of this complex and negatively regulates MAPK activation (Figure 1).
Although this hypothesis is compelling, it is important to keep in mind that Shc
could associate with SHIP through a different mechanism. For example, it has
been proposed that Shc PTB domain can bind the phosphorylated tyrosine Y917
and Y1020 on the NPXY motifs of SHIP.50 Studies using a SH2 domain deleted
SHIP mutant revealed that this domain is necessary for the NPXY motifs to
become phosphorylated48 and for SHIP to interact with Shc.50

Therefore, it

becomes difficult to exactly determine which domain between the SH2 and NPXY
domain is used by SHIP to bind to Shc.
6

Another protein with which SHIP

interacts through its SH2 domain is Gab1.51

However, in this case it is

impossible to rule out if SHIP and Gab1 associate directly or through
intermediary molecules, since they are found in a multi-protein complex involving
phosphorylated Shp-2, PI3K, and Shc.51,52

Figure 2. Schematic representing different SHIP isoforms structure.
SHIP, is SHIP and 145kDa.

(A) Full-length

(B)SHIPβ is app. 130kDa and lacks 183 amino acids
between

the

NPXY

motifs, resulting in the
deletion of a prolinerich domain and the
amino acids adjacent
to

the

motif,

first

NPXY

IGM,

which

would be important for
p85 subunit binding.
(C) SHIPδ is the result
of the deletion of all
the proline-rich regions and the last NPXY motifs. The last 62 amino acids at the cterminal are changed from the full length SHIP, caused by an out-of-frame 230 amino
acids deletion. Depending on the reports the SHIPβ and SHIPδ are either the result of
proteolytic cleavage37 or alternative splicing.53,54

(D) Stem cell-SHIP (s-SHIP) is

expressed from the same chromosomal region but has an alternative promoter/start site
than the SHIPα, situated in the intron5/6 of SHIPα. This was first proposed in a paper
we published in 200149 and then confirmed by Rohrschneider et al.55 A 125kDa isoform
that is probably generated through truncation of the 145 full-length SHIP c-terminal
exists, however this isoform has not been sequenced, thus the structure is not available.
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5’ Inositol Phosphatase

PI3K catalyzes the addition of a phosphate at the 3’ position on
Phosphatidyl Inositol(4,5) Phosphate (PI(4,5)P2), creating PI(3,4,5)P3, this molecule
allows the recruitment of pleckstrin homology (PH) domain containing proteins
(e.g.: Akt, phosphoinositide dependent kinase 1 (PDK1), Bruton’s tyrosine kinase
(Btk)),

which

can

then

stimulate

proliferation,

survival,

and

activation

pathways.10,56-59 SHIP, by removing the 5’ phosphate of PI(3,4,5)P3, can prevent
the recruitment of these effector molecules and negatively regulate some of PI3K
downstream signaling pathways.10,56-59 In particular, SHIP has been shown to
decrease Akt recruitment and phosphorylation, leading to a decrease in survival
and proliferation signaling.60,61

Furthermore, the degradation of PI(3,4,5)P3 by

SHIP after it is recruited to co-ligated B cell receptor (BCR) and FcγRIIB1 can
lead to a reduction in Btk membrane localization, which would prevent its
activation, resulting in a subsequent decrease in PLCγ2 activity and stopping of
calcium flux.62,63

On the other hand, the ability of SHIP to remove the 5’

phosphate of I(1,3,4,5)P4 could limit the extracellular entry of calcium and
negatively control cell activation.64-66 There is no requirement for SHIP to be
phosphorylated

before it can hydrolyze the 5’ phosphate of PI(4,3,5)P3 or

I(1,3,4,5)P4, suggesting that localization of SHIP in proximity to the target molecule
is the determining mechanism of activation.54

8

NPXY Motifs

NPXY stands for arginine (N), proline (P), any amino acid (X), and tyrosine
(Y), and there are two on the carboxyl-terminus of SHIP (Figure 2). This motif
can become tyrosine phosphorylated upon activation, which becomes a potential
binding site for some PTB domain containing protein.67-69 In this manner, it was
proposed that the PTB domain of Shc could interact with the phosphorylated
tyrosines of the NPXY motifs on SHIP, in particular Y917 and Y1020.2,50
Furthermore, a SHIP isoform, SHIPδ, in which the 2nd NPXY motif and all the
poly-proline rich stretch has been deleted can not bind to Shc.52 However, as
mentioned earlier, depending on the cell context, it appears that SHIP can also
interact with Shc, through its SH2 domain binding to the phosphorylated Y187 on
Shc, a site for which SHIP and Grb2 are competing in order to exert opposite
effects on the Ras/MAPK pathway.1 Although the nature of these conflicting
results will not be further discussed in this dissertation, they are worth mentioning
to emphasize that more work needs to be done to fully understand the function of
SHIP in the different cell context.

Another protein that has been found to interact with the NPXY motifs of
SHIP is the p85 subunit of PI3K.14,70,71 Of the two NPXY motifs present on the
carboxyl terminal region of SHIP, the first one is followed by a consensus
sequence for the binding of the p85 subunit of PI3K, isoleucine-glycine-
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methionine (IGM).53,71,72 It was shown that p85 PI3K subunit interacts with SHIP
only when the first NPXY region is tyrosine-phosphorylated.53,71

Proline Rich (PxxP) Region

PxxP motifs are spread between the 1st and 2nd and after the 2nd NPXY
motifs within the carboxyl terminus of SHIP (Figure 2). PxxP motifs are known to
interact with SH3 motifs,73 To this effect,

SHIP can associate with Grb2, a

protein containing two SH3 domains flanking an SH2 domain on each side.
Immunoprecipitation assays have shown that Grb2 can associate with SHIP and
s-SHIP.2,4,49

SHIP Isoforms

As mentioned above, several SHIP isoforms have been identified, mostly
through immunoblots. In humans it was shown that peripheral blood (PB) cells
expressed a 100kDa version of SHIP, while CD34+ acute myeloblastic leukemia
cells expressed 130kDa and 145kDa.74 In the murine system, most of the lower
molecular weight isoforms, the 110, 124, and 135kDa isoforms bear a deletion in
the c-terminus region, and appear to be generated from the full-length 145kDa
SHIP,3,5,53

either by proteolytic cleavage37,75,76 or alternative splicing.52

Importantly, the 110kDa SHIPδ isoform (Figure 2C), which lacks the proline-rich
10

region and the 2nd NPXY motifs at the carboxyl terminus, exhibit reduced
phosphorylation and interaction with Shc after stimulation of FD-FMS cells by MCSF.52 Lucas and Rohrschneider (1999) reported the co-expression of a 135kDa
and 145kDa SHIP isoforms in a series of macrophage, B cell progenitor, and Tcell cell lines.53 This 135kDa isoform results from the internal deletion of a PxxP
containing stretch between the 2 NPXY motifs due to alternative splicing. This
isoform, which was called SHIPΔ183, can still bind to Shc and Grb2 but has
reduced affinity for the p85 subunit of PI3K.53 This is explained by the deletion of
an important consensus sequence after the first NPXY motif, leading to a change
in the following amino acids from YIGM to YIAN.

The elimination of the

methionine at the +3 position after the tyrosine reduces the ability of p85 PI3K
subunit to bind SHIPΔ183.53

Even though most of the isoforms isolated seem to involve cleavage or
alternative splicing in the carboxyl-terminal of SHIP, another 110kDa isoform
lacking the SH2 domain was identified in human4 and in mice.49 The human
110kDa isoform, called SIP-110, isolated by Kavanaugh et al lacks 214 amino
acids at the amino-terminus, resulting in the absence of the SH2 domain.4 It was
proposed at the time that SIP-110 isoform resulted from alternative splicing of the
full length SIP-145 mRNA.4 In 2001, our laboratory published that murine ES
cells express a 110kDa SHIP isoform (calculated MW 104kDa), called s-SHIP.
This isoform lacks 263 amino acids at the amino-terminus.49 In that study, we
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proposed that s-SHIP and SIP-110 were homologues, and were both the result of
an alternative start site. The promoter region of that isoform being present in the
in the intron 5/6.49 This was confirmed in a study by Rohrschneider et al, which
showed that intron 5/6 had promoter activity able to drive the expression of a
reporter gene in stem/early progenitor cells in vivo.55

Importantly, s-SHIP is

expressed in ES cell and hematopoietic stem cells (HSC) but not in normal
lineage differentiated cells.49,55

This characteristic makes it a very important

isoform that certainly should be investigated further for its possible role in stem
cell biology.

Inositol Phosphatases with a Redundant Function to SHIP

SHIP2

A 150-155kDa protein with 38% amino acid sequence homology to SHIP1
was identified by Pasesse et al (1997), and was named SHIP2.77 It was later
found that this protein had already been isolated as 51C protein also called
inositol polyphosphate-like-protein1 (INPPL-1), which is an inositol phosphatase
with the potential to complement the Fanconi anemia group A gene defect.78
While murine SHIP1 is expressed from chromosome 1 and its human homologue
from chromosome 2, SHIP2 is expressed from Chromosome 7 in mouse and 8 in
human.

79

However, although SHIP2 reside on a different chromosome, it
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contains most of the hallmark domains of SHIP1. For example, SHIP2 has an
amino-terminal SH2-domain with 54% identity and a 5’inositol phosphatase with
64% homology to the one found in SHIP1.77 SHIP2 also has several poly-proline
rich stretches in its carboxyl terminal (up to 8), where SH3-domain containing
protein can bind and one NPXY motif, a site where PTB domain can bind. This
could account for SHIP2 ability to interact with Shc.80

Whereas SHIP1

expression appears to be restricted to hematopoietic cells, it was reported that
SHIP2 is ubiquitously expressed, being observed in hematopoietic cells, such as
T cells, B cells, thymus and spleen81 and in non-hematopoietic tissues such as
brain and skeletal muscle.77,82 Like SHIP1, SHIP2 has the potential to influence
many signaling pathways. For example, like SHIP1, SHIP2 has been shown to
associate with the ITIM domain of FcγRIIB in B cells under negative signaling.83
Furthermore, IL-3, c-KitL, and GM-CSF stimulated the phosphorylation and
interaction of SHIP2 with Shc in hematopoietic cells.80. Another example of the
importance of SHIP2, is its ability to be recruited to epidermal growth factor
(EGF) receptor where it hydrolyzes the 5’ phosphate of PI(3,4,5)P3 after EGF
stimulation of COS-7 cells. More importantly, SHIP2 has been shown to control
insulin receptor signaling in vitro84-87 and in vivo, in a knock-out model.88
Different groups have shown that SHIP2 over-expression led to a decrease in
insulin signaling whereas a SHIP2 deficiency led to an increase in insulin
sensitivity.84-89 It is important to mention that since SHIP2 interacts with different
molecules than SHIP1 and that it can not hydrolyze the 5’ phosphate of
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I(1,3,4,5)P4, even though these molecules have great homology they are not simply
redundant molecules, but have defined purpose in the cells.

Phosphatase and Tensin Homolog Deleted on Chromosome Ten

The defect observed in SHIP-/- mice is severe, but at the same time is
probably compensated for by different phosphates such as SHIP2, s-SHIP or
phosphatase and tensin homolog deleted on chromosome ten (PTEN). PTEN is
a 54kDa ubiquitously expressed tumor suppressor inositol phosphatase that can
hydrolyze the 3’ phosphate of PI(3,4,5)P3, thus, counteract PI3K activity and
contribute to the control of Akt activation.90 PTEN also has a modest capacity to
dephosphorylate tyrosine phosphorylated proteins.91 PTEN is one of the most
commonly inactivated genes in several type of cancers92 and a key regulator of
cell growth and apoptosis.93 The major function of PTEN appears to be the
reduction of basal PI(3,4,5)P3 levels and Akt activity in a constitutive manner,90 and
not upon stimulation by growth factor like SHIP. Therefore, its ablation leads to a
more severe phenotype than in SHIP-/- mice, in fact PTEN-/- are embryonic
lethal,94 further suggesting that PTEN is important for normal development.
Interestingly, PTEN+/- and SHIP-/- mice share many characteristics, suggesting
that the phenotype observed in both mice result mainly from the accumulation of
PI(3,4,5)P3.95,96
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Study of SHIP Function Using SHIP Knock-Out Models

The study of SHIP knock-out (KO) mouse models has given great insight
into SHIP function in the hematopoietic system.43,95,97 Although SHIP expression
is detectable during embryogenesis at day 7.5 post-coitus,98 SHIP KO mice are
viable.43,95,97 However, they suffer from a myeloproliferative disorder, that causes
an increase in macrophage progenitor and mature macrophage numbers in the
BM, spleen and periphery.95 These macrophages infiltrate the lung of SHIP-/mice, and this is the suspected cause for their demise at 8 to 12 weeks of age.95
Using SHIP KO mouse model, it was shown that SHIP negatively regulates the
phosphorylation and activation of Akt through downregulation of PI(3,4,5)P3 in B
cells,61 in myeloid cells,18 and NK cells.43 Huber et al also showed that through
binding to FcεRI in mast cells,40,44 SHIP can downregulate their degranulation
after stimulation of c-Kit receptor with its ligand.99 The stimulation of mast cells
leads to the activation of PI3K and the production of PI(3,4,5)P3, which can then
stimulate the entry of extracellular calcium,99,100 and the release of granule
content.

Interestingly, SHIP KO mice were also shown to suffer from

osteoporosis caused by hyper-resorptive osteoclasts.101 This could disrupt the
BM matrix and perturb the HSC niche.

Most of our studies were done using the SHIP-deficient mouse model
generated in our laboratory. These mice were created by targeting the promoter

15

and exon 1 of the SHIP gene using the Cre-loxP strategy and we refer to it as
SHIP-/- (Figure 3).43 In this model, the region to be deleted is flanked (floxed) by
two recombinase (Cre) recognition sites, called loxP, which were introduced by
homologous recombination in ES cells.102 In order to get deletion of the targeted
region, the 34 base pair loxP sites need to be inserted in the same orientation.103
Once a germline flox/flox or flox/+ animal is obtained, it is crossed with a Cre+/+
mouse, which result in the deletion of the targeted region. The resulting mice
can then be used to generate germline knockout mice.

This system allows

deleting or targeting the gene of interest either in the entire animal or specific cell
type dependent on the promoter that is used for Cre expression. The other SHIP
KO model used in our laboratory was a kind gift from Dr. Ravetch at the
Rockefeller University in New York. His team produced that model by targeting
the region that encodes part of the inositol phosphatase region using the CREloxP strategy (Figure 3).97 Consequently, this mouse model will be referred to as
SHIPΔIP/ΔIP. The SHIPΔIP/ΔIP mice were mainly used less frequently and mainly to
confirm the results obtained with SHIP-/- mice to ensure that different mutations of
the same gene lead to the same phenotype.
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Figure 3. Two SHIP KO models, SHIP-/- and SHIPΔIP/ΔIP. (A) Our laboratory created the
SHIP-/- model using 129SvJ ES cells, Cre-loxP recombinant technology. The promoter
region and the exon 1 of SHIP were targeted.43 The SHIPΔIP/ΔIP model was created using
the same technology
but targeting the exon
10
form

and

11,

part

which
of

the

inositol phosphatase
region.97 (B) Both of
these knockout mice
do not express SHIP.
(i) Western blot done on littermates of a mating between heterozygote male and female,
harboring a deletion of the promoter and first exon, SHIP-/-.43 (ii) Western blot done on
littermates of a mating between a heterozygote male and female, harboring a deletion of
exon 10 and 11, SHIPΔIP/ΔIP.97 The later mouse model was generated in the laboratory of
Dr. Ravetch at Rockefeller University, New York, USA.97
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RESULTS
Section I SHIP-Deficiency Enhances HSC Proliferation and Survival but
Compromises Homing and Repopulation

Introduction
HSC Development

HSC are responsible for the maintenance of the hematopoietic
compartment throughout an organism’s lifespan (Figure 4). These cells have the
ability to self-renew, differentiate into all hematopoietic lineage and to
reconstitute a lethally irradiated host. In the mouse, the embryonic or primitive
HSC appear in the yolk sac at day E7 of embryonic development.104,105 These
cells participate in transient hematopoiesis during embryogenesis giving rise
mainly to nucleated erythrocytes,106 although some studies have shown that
putative yolk sac HSC have long-term multilineage repopulation capacity,107
suggesting that they have he potential to differentiate into several hematopoietic
lineage.

At day E10, the definitive HSC is found in the aorta-gonad-

mesonephros (AGM).108,109 Only these HSC will have the ability to establish
definitive hematopoiesis and to reconstitute a lethally irradiated adult host.104,108110

Later during fetal development the definitive HSC migrate to the fetal liver, to

the spleen and shortly thereafter birth all hematopoiesis is concentrated mainly in
18

the BM.104

The maintenance of the hematopoietic compartment depends on

HSC homeostasis, the balance between self-renewal, proliferation, apoptosis,
and migration (i.e. homing and mobilization) of HSC. Several factors responsible
for HSC homeostasis have been identified, nevertheless more information is
needed.

Figure 4. Hematopoietic compartment. HSC have the potential to self-renew without
limits, differentiate and produce all the cells necessary for a functional hematopoietic
compartment. This differentiation occurs through a series of intermediaries (often called
progenitors), which usually have the potential to self-renew with limitations and to
differentiate into a defined cell type.
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Cytokines Impacting HSC Self-Renewal

It is well accepted that the niche in which the HSC reside in the BM is
responsible for the retention of HSC and their ability to self-renew, differentiate,
or apoptose. Cell-to-cell contact and external signaling plays a major role in that
process. Several cytokines have been shown to influence HSC proliferation and
self-renewal in vitro and in vivo. In fact, several in vitro studies have shown that
TPO alone or in combination with c-KitL, IL-3, or Flt3L111-115 can stimulate the
proliferation of early human and murine hematopoietic progenitors.116-127 Most
importantly, expansion of early progenitor cells in the presence of TPO with cKitL or Flt3L confer these cells with the ability to self-renew, to retain a primitive
phenotype and maintain the capacity for multilineage differentiation for a defined
number of cell division.116,119-121,123-125 It was also shown that tumor necrosis
factor-α (TNF-α) can stimulate the self-renewal and proliferation of human
CD34++CD38- in vitro in the presence of IL-3, potentially in a synergistic
manner.128 Most importantly, maintenance of hematopoiesis in vivo depends on
the presence of osteoblast and stromal cells that will form the niche.

This

microenvironment will promote HSC homeostasis. Furthermore, several factors
that are important for maintenance of HSC have also been shown to impact
homing and retention of HSC to the BM niche.
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BM Homing and Retention of HSC

The homing process was characterized as a 3 step process; 1) Loose or
rolling interaction of cells with vascular endothelium, 2) Firm adhesion to the
vessel or sinus, 3) Diapedesis through the endothelial layer.129 This process first
requires the presence of specific cytokines and of cell adhesion molecule (CAM)
that will mediate the associate of HSC with the stromal cells and osteoblasts that
compose the niche in the endosteal region in the BM that support HSC
homeostasis.130-135 To this effect, HSC can interact with a series of molecules
produced by the BM stroma such as extracellular matrix (ECM) components,
CAM mediating cell-cell adhesions, and endothelial selectins.

The ECM

components are fibronectin,136,137 hyaluronic acid,138 laminins,139 collagen, and
thrombospondin.140 The CAM mediating cell-cell adhesions include the
intracellular cell adhesion molecule-1 (ICAM-1/CD54) and vascular cell
endothelial molecule-1 (VCAM-1 or CD107).141,142 The endothelial selectins are
P-selectin/CD62P and E-selectin/CD62E.143,144

All of these molecules are

ligands for receptors present on HSC. These receptors, once engaged will lead
to HSC attachment and establishment in the BM niche and thus, contribute to
HSC homeostasis. For example, very-late-antigen 4 (α4β1, CD49d/CD29 (VLA4)) is expressed by hematopoietic cells including HSC and can bind fibronectin
and VCAM-1 present on endothelial cells. VLA-4 can promote initial capture,
rolling and firm cell adhesion to the endothelial cells.145 In previous studies, in
vitro stimulation of murine BM stem/progenitor cells with different cytokines was
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shown to induce cell cycle, decrease VLA-4 expression and resulting in
compromised engraftment.146,147 Most importantly it was shown that engagement
of VLA-4 an VLA-5 receptors can lead to HSC quiescence,148 an important
aspect of HSC biology.

Most importantly, HSC quiescence protects the

compartment against external insult and insure the organism that the
hematopoietic compartment will be replenish once the insult is cleared.

Proper homing of the HSC to the BM also depends on the presence of a
chemokine, SDF-1 also called CXCL-12 and the engagement of its receptor on
HSC, CXCR4.

The CXCR4 receptor induces cell migration towards an

increasing gradient of SDF-1.149 Treatment of NOD/SCID mice with SDF-1 leads
to the mobilization of HSC to PB150 and treatment of human HSC with antiCXCR4 antibody prior to transplantation in NOD/SCID mice results in HSC
engraftment failure.151

Furthermore, CXCR4 and SDF-1-deficient mice are

embryonic lethal since HSC fail to migrate from the fetal liver to the BM, where
definitive hematopoiesis would take place.

Interestingly, SHIP-/- myeloid

progenitor cells have been shown to migrate more efficiently towards SDF-1
compared to WT myeloid progenitors.152

Furthermore, SHIP appears to be

recruited to the membrane upon CXCR4 engagement by SDF-1.27

SHIP in HSC Biology
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As mentioned earlier, the survival of an organism is dependent upon the
ability of HSC to replenish the blood compartment on a daily basis (Figure 4). To
accomplish this task, HSC must maintain a fine balance between three possible
fates: self-renewal, differentiation or senescence. Although the decision process
that determines the fate of an HSC clone remains to be completely defined,
several molecules are already known to play a role in this process, including
components of the HSC microenvironment or niche. This niche consists of both
extra-cellular matrix molecules and cells, such as osteoblasts and stromal cells
that produce cytokines and chemokines important for the maintenance of the
HSC pool.131-135

These microenvironmental or external cues engage receptors on HSC,
leading to the activation of signaling pathways governing cell proliferation, selfrenewal, differentiation, mobilization and BM retention.135

Some of these

pathways, such as those initiated by c-KitL,153 SDF-1,154 IL-3,155 Flt-3L,111-115 and
TPO,17 result in the activation of PI3K and the formation of PI(3,4,5)P3. Therefore,
SHIP may influence these pathways in HSC.47,152 SHIP is a 145kDa protein
primarily expressed by cells of the hematopoietic system,3 including HSC,49 that
can associate with various adapter proteins, scaffold proteins, or receptors
following activation of hematopoietic cells.18,152 Formation of these complexes
enables SHIP to hydrolyze the 5’phosphate on PI(3,4,5)P3,2,3 thus preventing
membrane recruitment and activation of pleckstrin homology domain containing
kinases that serve as effectors of PI3K signaling. This activity permits SHIP to
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limit the survival, activation, differentiation and/or proliferation of hematopoietic
cells.47 Thus, we hypothesized that SHIP might also influence these processes
in the HSC compartment. Previous studies reported that SHIP-/- whole bone
marrow (WBM) cells do not reconstitute lethally irradiated mice as well as wildtype (WT) WBM in a non competitive setting.156 Furthermore it was reported that
SHIP-/- WBM has comparable numbers of competitive-repopulating-units (CRU)
relative to WT littermates in a limiting-dilution assay, which uses compromised
competitor cells.156

However, because these analyses were performed with

WBM rather than purified HSC, they did not assess whether SHIP-/- HSC are
defective for repopulation in a WT environment. Thus, it is not possible from
these previous studies to conclude that SHIP plays a direct role in signaling
pathways essential for HSC function.

To study the role of SHIP in HSC we used SHIP-/- mice generated by a
Cre-lox mutation strategy.43

We found that SHIP-/- mice contain significantly

more HSC in their BM, spleen, and blood as measured by flow cytometry. We
also observed that a greater proportion of SHIP-/- HSC enter the cell cycle
compared to WT HSC. Since it was shown in previous studies that SHIP-/- BM
contains reduced HSC activity relative to WT BM,156 it became important to
assess the function of SHIP-/- HSC in different assays. We found that when
purified SHIP-/- HSC or WBM are transplanted into lethally irradiated mice, they
failed to compete effectively with WT HSC or BM cells for long-term multi-lineage
repopulation of the hematopoietic compartment.
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These results might have

suggested that the absence of SHIP causes accelerated senescence of the HSC
compartment. However, we observed fewer apoptotic HSC in SHIP-/- BM as
compared to WT BM. We then assessed the ability of SHIP-/- HSC to reach the
BM niche, where they encounter the proper environment to support their function.
In vivo homing studies performed using purified stem/progenitor cells suggest
that SHIP-/- cells home to the BM with a decreased efficiency compared to WT
cells. Most interestingly, we also observed that SHIP-/- HSC have significantly
lower surface expression of CXCR4 and VCAM-1, key receptors for homing and
retention of hematopoietic cells in the BM.151,157,158 Therefore, SHIP plays an
important role in regulating HSC proliferation, survival, self-renewal, as well as
BM homing and retention.
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Aims:
1) Quantitate the HSC compartment in different hematopoietic organs of SHIPdeficient mice as compared to WT by flow cytometry.
2) Assess if SHIP-/- HSC are functional in a transplant assay. This is the only in
vivo assay to measure HSC ability to self-renew and differentiate into cells of
the hematopoietic compartment.
3) Determine why SHIP-/- HSC do not engraft as efficiently as WT HSC; Are they
short-term HSC?, do they lack the ability to differentiate in a transplant
setting?, are they more prone to apoptosis due to the osteoporotic phenotype
observed in SHIP-/- BM?, are they deficient in their ability to engraft?

Results

SHIP-/- Mice Have an Expanded HSC Compartment
We initially quantitated HSC numbers based on a phenotype established
by Morrison et al., Lin-/lowThy1+c-Kit+Sca1+ (KTLS),159 which are highly enriched
for long-term repopulating HSC (LT-HSC) activity.159 We found that SHIP-/- mice
have an increased percentage and absolute number of KTLS cells in their BM,
spleen (Table 1) and PB (data not shown).
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Table 1. Increased numbers of HSC cells in the BM and spleen of SHIP-/- mice
compared to WT littermates. n at least 3 for each genotype, ♦ spleen
% over WBM cells
SHIPΔIP/ΔIP

WT

p

BM

0.276±0.024

0.041±0.008

0.0005

46.24±8.01

16.95±4.18

0.0343

spl♦

0.1767±0.0481

0.01±0.001

0.0255

89.2±28.2

2.93±0.282

0.0375

WT

p

Population
-

+

Lin Sca1
+
low
c-Kit Thy1

SHIP

Population
-

+

Lin Sca1
+
low
c-Kit Thy1

Abs. #/pair of femur + tibia
3
or Abs#/spleen (x10 )
ΔIP/ΔIP
SHIP
WT

-/-

WT

p

SHIP

-/-

p

BM

0.4114±0.0353

0.0725±0.025

<0.001

205.3±33.9

37.9±15.3

0.001

spl

0.0957±0.0131

0.0142±0.0040

0.004

50.90±9.25

5.80±1.92

0.01

BM

0.2860±0.0398

0.1340±0.0202

0.01

221.4±45.9

103.0±72.2

0.03

spl

0.0827±0.0141

0.027±0.002

0.02

52.10±7.89

13.58±0.75

0.008

BM

0.019±0.002

0.0068±0.0006

0.001

7.84±0.95

2.76±0.30

0.001

spl

0.0020±0.0003

0.0002±0.0001

0.005

5.53±0.073

0.289±0.087

0.002

Lin Sca1 c-Kit
+
CD48 CD150

+

BM

0.0008±0.0001

0.0004±0.0001

0.04

0.35±0.019

0.164±0.062

0.045

Side population
(SP)

BM

0.0565±0.0044

0.0290±0.0044

0.004

26.7±4.7

12.5±2.4

0.035

-

+

Lin Sca1 c-Kit
Flk2

-

+

Lin Sca1 c-Kit
CD48

-

+

+

+

BM of SHIP-/- mice contained 6-fold more KTLS cells than WT controls
P

(Table 1).

In the spleen of SHIP-/- mice, we observed a greater than 6-fold

increase in the percentage and absolute numbers of KTLS cells (Table 1). A
comparable scenario was seen in the PB, where KTLS cell percentage was
increased by 2.5–fold as compared to WT littermates (data not shown). A similar
expansion of the KTLS compartment was observed in SHIPΔIP/ΔIP mice, another
germline SHIP mutant model with a different genetic background.97 As for the
SHIP-/-, SHIPΔIP/ΔIP BM and spleen exhibited a significant increase in KTLS cells
when compared to WT control (Table 1). The percentage of KTLS present in
SHIPΔIP/ΔIP BM and spleen were 6.7 and 2.7-fold higher than observed in WT
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control. Furthermore, KTLS absolute numbers were increased 18.2-fold in the
BM and 30.4-fold in spleen of SHIPΔIP/ΔIP mice as compared to WT controls.

Although Thy1.2 expression can be detected on HSC from C57BL6/J
mice, surface expression is lower, making negative and positive distinction more
difficult than for the Thy1.1 allele.160,161 Thus, we also quantified HSC numbers
using different phenotypes, including the immunophenotype defined by
Christensen et al:160 Lin-/lowFlk2-c-Kit+Sca1+ (KFLS). KFLS cells, as opposed to
KTLS, can be used regardless of genetic background.160 We found that SHIP-/mice also exhibited an increased percentage and absolute number of KFLS cells
in their BM and spleen (Table 1). KFLS cell numbers are expanded by 2-fold in
the BM of SHIP-/- mice relative to WT mice. We also observed that both the
percentage and absolute numbers of KFLS cells in SHIP-/- spleens were
increased by more than 3-fold as compared to WT spleens (Table 1). In addition,
Kiel et al recently published a new phenotype to identify HSC that relies on the
differential expression of the SLAM family receptors, CD48 and CD150, by HSC
and MPP.162 We observe a 2.8-fold increase in the number of KLSCD48- cells in
SHIP-/- BM compared to WT BM (Table 1, Figure 5A, B). Moreover, the
percentage and absolute numbers of KLSCD48- cells are increased by 8.7 and
19-fold, respectively in SHIP-/- relative to WT spleen (Table 1, Figure. 5A, B).
When using the KLSCD48-CD150+ immunophenotype we detect a 2-fold
increase in the number of HSC in the BM of SHIP-/- BM as compared to WT
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(Table1). In order to confirm our observations made using immunophenotypes
relying on surface marker expression, we assessed the level of HSC using the
side population (SP) phenotype. Identification of SP cells relies on the function
of a transporter protein that exclude the dye Hoechst 33342,163,164-- these cells
are enriched ~1000-fold for LT-HSC activity compared to WBM cells.163 When
comparing SHIP-/- vs. WT BM, we observed a 2-fold increase in the percentage
and absolute number of SP cells in SHIP-/- BM (Table 1). Thus, analysis of five
different HSC phenotypes159,160,162,163 demonstrated a preferential expansion of
the LT-HSC compartment in SHIP-/- mice. These observations implicate SHIP in
the control of HSC compartment homeostasis.
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Figure 5. Significant increase in the percentage and absolute number of KLSCD48- cells
in SHIP-/- BM. (A) Representative
FACS plots showing detection of
KLSCD48- HSC in SHIP-/- and WT
BM. (B) Percentage and absolute
number of KLSCD48- cells in the
BM (per femur and tibia pair) and
spleen (Spl) of SHIP-/- (square) and
WT (triangle) mice. Data acquired
on a FACS Aria with DiVa (BD
Biosciences,

San

Jose,

CA)

software, analyzed with FlowJo
(Tree Star Inc., Ashland, Oregon).
(C) Histogram of DNA content in
SHIP-/- and WT KTLS cells. (D) Bar
graph showing the percentage of
SHIP-/-

(black)

or

WT

(grey)

KTLS/KFLS cells in each stage of
cell cycle as calculated using the
Watson Pragmatic model in the
FlowJo cell cycle platform.

Data

acquired on FACS Vantage with
DiVa software (BD Biosciences).
Significance was established using
the unpaired student t test (Prism 4
(GraphPad Software, San Diego,
CA,

USA)).

**p<0.001,
+++p<0.0005.
n≥3).
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***p<0.0001,
*p<0.01,

and

(mean ± SEM,

Since SHIP has been shown to negatively regulate proliferation of different
cell types,18 its deficiency could lead to an increase HSC cell cycle activity. In
agreement with this, we observed that SHIP-/- BM contained a greater proportion
of KTLS in the S/G2 phase, 23.2±1.5% as compared with 14.1±0.1% for WT BM
(Figure 5C). This study directly demonstrates that SHIP-/- HSC themselves have
increased cycling activity relative to WT.

This is consistent with findings of

Helgason et al that CRU in SHIP-/- BM are more sensitive to 5-fluorouracil
treatment.156

In SHIP-/- BM, we also observed a significant decrease in the
P

proportion of HSC in the quiescent (G0/G1) stage: a subset of cells enriched for
long-term multi-lineage engraftment relative to those that have entered the cell
cycle.147,165-167

Induced Deletion of SHIP During Adulthood Leads to an Increase in KFLS
Numbers in Hematopoietic Organs

In the previous section, we studied the impact of SHIP ablation in germline
knockout mice.

Although this model is very useful, SHIP is ablated during

embryogenesis, which could lead to the disruption of cell function or signaling
pathways necessary for normal development. Thus, we also assessed the levels
of HSC in an inducible Mx1-Cre-loxP SHIP knockout model, where SHIP is
deleted only during adulthood, allowing for the mice to develop normally. In this
model, the region to be targeted is flanked by loxP sites, and the Cre expression
is under the control of the Type 1 interferon-inducible Mx1 promoter.43,102,103
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Treatment of these mice with a double stranded RNA homolog, polyinositolic
polycytidylic acid (polyIC), leads to the induction of an endogenous anti-viral
Type 1 interferon response, which results in Mx1 promoted Cre expression and
Cre-mediated recombination of the target gene, in this case the SHIP promoter
and first exon.102,103. This deletion results in the ablation of SHIP expression.
Twenty-one days after polyIC treatment, the mice were euthanatized and HSC
were quantitated by flow cytometry (Figure 6). As a negative control, we used
MxCre- mice treated with polyIC, however, since the MxCre promoter/gene is
missing, no rearrangement of the loxP site can take place.

In the three

hematopoietic organs examined, BM, PB and spleen, we observed a significant
increase in the percentage of KFLS cells in MxCre+fl/fl mice as compared to
MxCre-fl/fl. In the BM of SHIP-ablated mice, we observed a subtle but statistically
significant increase of 1.5-fold in the percentage and absolute number of KFLS
cells as compared to MxCre- mice (Figure 6 a, b). Interestingly, the spleen and
the PB of SHIP-ablated mice exhibited the greatest increase in the percentage of
KFLS cells. Indeed, there was a 9.8 and 16.7-fold increase, respectively, in the
percentage and in the absolute numbers of KFLS cells in SHIP-ablated spleen as
compared to control (Figure 6 b). In the PB of SHIP-ablated mice, we observed
a 12.6-fold increase in the percentage of KFLS cells (Figure 6 b). This result is
consistent with these two organs being more dynamic than the BM, and
therefore, responding more rapidly to the absence of SHIP.

Furthermore, in

another experiment, we determined that the percentage and absolute number of
KLSCD48- cells were significantly increased 3.2-fold and 5.6-fold, respectively, in
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SHIP-ablated BM. In these same mice, we observed a 3.9-fold augmentation in
KLSCD48- cells in the PB. KLSCD48- cells were not increased to the same
levels than KFLS in the PB, this might result from the fact that CD48 appears to
be present on cycling HSC.168 Since most of the HSC that are mobilized to the
PB usually are proliferating, it is difficult to find the KLSCD48- cells in the PB.
Nevertheless, we observed that SHIP ablation during adulthood results in an
enlargement of the HSC compartment, suggesting that the HSC increase
observed in SHIP-/- germline mice is not the result of a developmental defect.
These results also suggest that the effect of SHIP ablation on the HSC
compartment is intrinsic to the HSC.
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Figure 6. Significant increase in the percentage and absolute number of HSC in SHIPablated BM, spleen and PB. MxCre+ and MxCre- mice with floxed SHIP alleles were
treated 3 times with 625 μg of polyIC in the course of a week, 21 days prior to being
analyzed. (A) Representative FACS plots showing detection of KFLS HSC in SHIPablated and MxCre- BM. (B) Percentage of KFLS cells in the BM, spleen and PB of
SHIP-ablated (black) and MxCre- (grey) mice, and absolute number of KFLS cells in BM
(per femur and tibia pair) and spleen. (C) Representative FACS plots showing detection
of KLSCD48- HSC in SHIP-ablated and MxCre- BM. (D) Percentage of KLSCD48- cells
in the BM and PB of SHIP-ablated (black) and MxCre- (grey) mice, and absolute number
of KLSCD48- cells in BM (per femur and tibia pair). Data acquired on a FACS Calibur
with CellQuest software (BD Biosciences), analyzed with FlowJo.

Significance was

established using the unpaired student t test (Prism 4). *p<0.01, ++ p<0.005, and
+p<0.05. (mean ± SEM, n≥3).
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SHIP-/- BM Cells Show Decreased Ability to Reconstitute the Hematopoietic
Compartment of Lethally Irradiated Recipients

It was previously reported that SHIP-/- BM cells have a lower ability to
reconstitute irradiated mice after transplantation, but contains similar CRU
activity as compared to WT BM when measured by limiting-dilution assay.156
Since these results are inconsistent with our finding that SHIP-/- BM contains
increased number of HSC (Table 1, Figure 5), we addressed this discrepancy by
measuring the ability of SHIP-/- HSC to accomplish long-term multi-lineage
repopulating activity. We first performed a well-defined CRU assay as described
by Harrison169 to assess the level of repopulation activity in WBM. WBM is used
for the CRU assay and therefore is not dependent on isolation of HSC based on
cell surface markers, whose expression can be altered by genetic mutation of
unrelated loci.170 Using this assay, we observed that SHIP-/- BM cells did not
reconstitute recipients as efficiently as WT littermates, with a significant reduction
of 4.4-fold in CRU numbers in primary transplant recipients (Figure 7A, B).
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Figure 7. SHIP-/- WBM cells have compromised reconstituting activity. (A) CRU activity
calculated based on the percentage of
global repopulation in the PB by donor
WBM cells (SHIP-/- (black); WT (grey)). (B)
Percentage of global repopulation of PB by
SHIP-/- (black) and WT (grey) donor in a
CRU assay.

(C) Percentage of lymphoid

and myeloid PB cells derived from SHIP-/(black) or WT (grey) WBM 16 weeks after
transplantation in a CRU assay.

Data

acquired using FACS Calibur, CellQuest
software (BD Biosciences) and analysis
done with FlowJo. Significance was established using the unpaired student t test (Prism
4): ***p<0.0001, **p<0.001, and +p<0.05. (mean ± SEM).

SHIP-/- BM cells showed a significant decrease in long-term reconstitution
of both the lymphoid and myeloid cell lineages. For example, 16 weeks after
transplantation only 13.2±2.7% of B cells were SHIP-/- derived (CD45.2+)
compared to 60.1±2.8% for WT (CD45.1+) WBM, T cell repopulation were
21.2±4.7% SHIP-/- derived vs. 39.7±4.1 for WT and 34.7±5.2% of myeloid cells
were SHIP-/- BM derived vs. 57.4±2.8% from WT (Figure 7C). The reduction in
the SHIP-/- B cell representation observed in the CRU assay agrees with other
studies showing that SHIP deficiency negatively impacts early B-lineage
development.171 We did not observe that SHIP-/- BM cells had enhanced myeloid
repopulation relative to WT BM cells (Figure 7C). However, we did observe a
bias toward myeloid differentiation within cells derived from SHIP-/- BM, where
59.7±2.7% of the CD45.2+ in the SHIP-/- WBM recipients were Mac1+/Gr1+
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compared to 24.1±2% for WT BM recipients. This occurred at the expense of the
B cell lineage, for which only 25.3±1.5% of CD45.2+ cells were B220+ compared
to 61.8±3.1% for WT (data not shown). The overall reduction in long-term multilineage repopulation by SHIP-/- BM cells demonstrates that despite the increase
in HSC numbers observed (Table 1 and Figure 5A, B), HSC activity is
significantly compromised in these mice (Figure 7A, C).

Measuring HSC activity by transplantation of WBM from mutant mice can
be confounded by the fact that the mutation can endow lineage-committed
progenitor cells with properties that may obscure the observation of
compromised HSC function.172 This is a concern when working with SHIP-/- BM
as the SHIP mutation enhances myelopoiesis, causing an increase in myeloid
progenitors, which have enhanced survival.95 Therefore, analysis of HSC activity
in SHIP-/- mice must also be assessed with purified HSC to rule out these
potential experimental artifacts. To directly assess whether SHIP expression by
HSC is required for long-term multi-lineage repopulation and self-renewal, we
directly compared the repopulating potential of purified HSC from SHIP-/- and WT
mice. Thus, CD45.2 SHIP-/- KTLS or KFLS cells were transplanted into lethally
irradiated CD45.1/CD45.2 WT recipients with an equivalent number of CD45.1
WT KTLS or KFLS and Sca1- CD45.1/CD45.2 support cells. This assay, the
direct competition (DC) assay,173 directly compares the capacity of geneticallymodified HSC to compete with WT HSC for engraftment and long-term multilineage repopulation. The level of repopulation in recipients PB was assessed at
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regular intervals (Figure 8A), and at sixteen to twenty weeks post-transplant, we
observed that global repopulation by SHIP-/- KTLS was reduced by 15-fold
relative to WT KTLS (Figure 8B).

Figure 8. SHIP-/- purified HSC have compromised reconstituting activity. (A) FACS plots
show the level of PB reconstitution 16-weeks after KTLS transplantation in a
representative DC assay mouse using sorted SHIP-/- and WT KTLS. (B) Percentage of
global reconstitution 16 weeks after transplantation
of sorted KTLS (SHIP-/- (black) and WT (grey))
(n=11 over 2 different experiments). (C) Proportion
of lymphoid and myeloid PB cells derived from
SHIP-/- (black) or WT (grey) WBM 16-weeks after
KTLS transplantation.
reconstitution

12

(D) Percentage of global

weeks

after

sorted

KFLS

transplantation (SHIP-/- (black); WT (grey)) (n=7).
Data acquired using FACS Calibur, CellQuest
software (BD Biosciences) and analysis done with
FlowJo.

Significance was established using the

unpaired

student

t

test

(Prism

4):

++p<0.005 and +p<0.05. (mean ± SEM).
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*p<0.01,

Reconstitution of different lineage by SHIP-/- KTLS was also significantly
reduced (Figure 8C).

Thus, SHIP-/- KTLS are capable of multi-lineage

reconstitution, but are unable to sustain this activity for extended periods when in
direct competition with WT KTLS (Figure 8C). Furthermore, SHIP-/- cells did not
dominate the myeloid compartment as might have been expected from previous
studies,95,156 with only 1% of Mac1+/Gr1+ cells being derived from SHIP-/- KTLS
vs. 21% from WT KTLS (Figure 8C). This indicates that although SHIP-/- myeloid
lineage progenitors have enhanced survival and can prevail over seriallytransplanted competitors,95,156 they are, nonetheless, unable to out-compete
normal WT myeloid progenitors when derived from purified HSC in a chimeric
transplant setting. As with KTLS cells, long-term global repopulation by SHIP-/KFLS is significantly reduced (Figure 8D). These results demonstrate that SHIP
expression is required by HSC in order to sustain long-term multi-lineage
repopulation.

SHIP-/- HSC do not Exhibit Characteristics of Premature Differentiation

As HSC go down the path of differentiation, they lose the ability to selfrenew and exhibit a higher proliferative state. Since we observed that SHIP-/HSC proliferation is increased and engraftment is perturbed, we assessed by
flow cytometry if SHIP-/- KTLS exhibited immunophenotypic characteristic of early
differentiation. It has been shown that KTLS cells with high levels of c-Kit (c-Kithi)
are enriched for LT-HSC activity, as opposed to the c-Kitlo population that is not
39

able to support long-term multi-lineage repopulation.174 This assay revealed that
a significantly greater proportion of SHIP-/- TLS were c-Kithi as compared to WT
KTLS cells (Figure 9A, B). There was a greater than 3 fold increase in the
percentage of c-KithiTLS in the SHIP-/- BM as compared to WT BM (Figure B).

Figure 9. More SHIP-/- TLS cells express high levels of c-Kit as compared to WT. (A)
Representative FACS plots showing detection of Lin-Thy1+Sca1+c-Kithigh and LinThy1+Sca1+c-Kitlow. (B) Percentage (left column) and absolute number (right column) of
Lin-Thy1+Sca1+c-Kithigh (top row) and Lin-Thy+Sca1+c-Kitlow cells).
calculated for 1 pair of femur and tibia.
software, analyzed with FlowJo.

Absolute numbers

Data acquired on a FACS Aria with DiVa

Significance was established using the unpaired

student t test (Prism 4). ***p<0.0001 and ++p<0.005. (mean ± SEM, n=4).
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In fact, in SHIP-/- mice 95% of KTLS cells expressed high levels of c-Kit
while only 78% of KTLS in WT mice (Figure 9A). This analysis revealed that the
percentage and the mean absolute number of c-KithiTLS cells in SHIP-/- WBM
cells were 4 and 4.6 fold higher, respectively, as compared to WT littermates
(Figure 9B). As LT-HSC differentiate towards short term (ST)-HSC phenotype,
they begin expressing increasing amount of Mac-1 on their surface, they
proliferate at a faster rate and have a reduced ability to self-renew.159 Therefore,
we assessed the level Mac1 expression on SHIP-/- KTLS cells in order to better
characterize the HSC compartment in these mice. After gating on live KTLS
cells, we looked at the level of Mac1 expression on SHIP-/- and WT HSC by flow
cytometry. Since the histogram for Mac1 on KTLS was unimodal, we assessed
the level of Mac1 expression using the mean fluorescence intensity (MFI) instead
of percentages (Figure 10A, B). Our results revealed that SHIP-/- KTLS cells
express comparable levels of Mac1 molecules on their surface as WT KTLS
(Figure 10A, B), suggesting that the proportion of ST-HSC contained in SHIP-/KTLS fraction is not increased as compared to WT control. Thus, according to
this phenotypic assay, SHIP-/- KTLS do not exhibit characteristic of premature
differentiation.
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Figure 10. SHIP-/- KTLS express similar levels of Mac1 as compared to WT KTLS. (A)
Representative FACS plots showing detection of Mac1 expression (histogram) on KTLS.
(B) Two representative overlay histogram of Mac1 expression for SHIP-/- (black) and WT
(grey) KTLS. (C) Graph comparing the MFI of Mac1 expression for SHIP-/- and WT
KTLS.

Data acquired on a FACS Aria with DiVa software, analyzed with FlowJo.

Statistical analysis was done using the unpaired student t test (Prism 4). (mean ± SEM,
n=4).
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SHIP-/- HSC Self-Renew to a Lesser Extent than WT HSC in Transplanted Mice

Our data suggest that SHIP-deficient mice have increase in HSC number
and proliferation. However, once transplanted these cells did not reconstitute the
host was well as WT HSC. One of the hypothesis proposed to explain these
observation was that SHIP-/- HSC might be unable to differentiate. In that case,
SHIP-/- HSC would be present in the BM and self-renew without having the ability
to differentiate and reconstitute the host PB. Therefore, we assessed the level of
reconstitution of the different hematopoietic organs of transplanted mice at least
6 months after transplantation.
sacrificed

and

their

spleen,

Three of the CRU transplanted mice were
BM

and

PB

were

assessed

for

granulocyte/macrophage and lymphoid reconstitution. This assay revealed that
every lineage in every organ except for Mac1Gr1 in PB was significantly less
reconstituted by SHIP-/- WBM cells as compared to WT WBM cells (Figure 11A).
P

The majority of the lineages were reconstituted to less than 25% by SHIP-/- WBM
cells.
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Figure 11. SHIP-/- HSC do not engraft and self-renew as well as WT HSC, although
transplanted in equal numbers.

(A) CD45.1 mice were irradiated (1000 rads) and

transplanted with 1 million CD45.2 SHIP-/- and 1 million CD45.1 WT WBM. Percentage
of lymphoid and myeloid PB, spleen and BM cells derived from SHIP-/- (black) or WT
(grey) WBM >16 weeks after transplantation. (B) Percentage of KTLS cells in the BM
that are derived from SHIP-/- (black) or WT (grey) WBM. (C) CD45.1xCD45.2 mice were
irradiated (600 and 400 rads at 3-hour interval) and transplanted with 2x105 CD45.2
SHIP-/- and 2x105 CD45.1 WT KTLS cells with 4x105 CD45.1xCD45.2 Sca1- cells. First
bar graph shows the percentage of KTLS cells derived from SHIP-/- (black) or WT (grey)
P

KTLS cells. Second bar graph Absolute numbers of SHIP-/- and WT KTLS found in 1
pair of femur and tibia SHIP-/- (black) or WT (grey) KTLS cells.
compares fold expansion for SHIP

-/-

-/-

and WT KTLS cells SHIP

Third bar graph

(black) or WT (grey)

KTLS cells. Data acquired using FACS Vantage, DiVa software and analysis done with
FlowJo.

Significance was established using the unpaired student t test (Prism 4):

*p<0.01, +++p<0.0005, ++p<0.005 and +p<0.05. (mean ± SEM, n=3)
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We then had to consider that the SHIP-/- HSC could self-renew but not
differentiate as efficiently as WT. Thus, we observed the level of reconstitution of
the KTLS compartment. Briefly, BM cells were enriched for HSC by lineage
depletion using the AutoMACS (Miltenyi Biotec, Auburn, CA, USA), and then
stained for KTLS, CD45.1 and CD45.2 in the presence of DAPI. This assay
revealed that the percentage of KTLSCD45.2+ (SHIP-/-) over the total amount of
KTLS cells was 13.8 ± 4.8%, while 57.3 ± 7.2% of KTLS were CD45.1+ (WT)
(Figure 11B). Therefore, the capacity of SHIP-/- WBM cells to reconstitute the
HSC compartment of a transplanted mouse is significantly lower than he one of
WT WBM cells, p=0.007 (Figure 11B).

This result correlates with the lower

reconstitution of the different hematopoietic organs by SHIP-/- CD45.2 cells
(Figure 11A). In the CRU assay the recipient is CD45.1, therefore, we could not
totally exclude that a portion of CD45.1+ KTLS came from the host. To address
this issue, we assessed the level of KTLS reconstitution in DCA transplanted
mice more than 12 months after transplantation. In this case the recipients are
CD45.1xCD45.2, thus WT (CD45.1) and SHIP-/- (CD45.2) cells can be
differentiated from the host. In these transplanted mice, it was also obvious that
CD45.2 SHIP-/- KTLS cells composed a significantly reduced portion of the KTLS
compartment as compared to WT (Figure 11Ci). The absolute numbers of SHIP/-

KTLS cells contained in one hind limb were reduced 6.4-fold as compared to

the number of WT KTLS (Figure 11Cii).

Furthermore, the fold expansion of

KTLS cells calculated based on the amount of transplanted KTLS cells and the
total amount of KTLS recovered in the recipients revealed that SHIP-/- KTLS only
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expanded 44 ± 25-fold compared to 287 ± 56 fold for WT KTLS. Thus, SHIP-/KTLS did no self-renew with the same efficiency than WT KTLS p=0.008 (Figure
11Ciii).

These results confirm that SHIP-/- WBM and KTLS cells cannot

reconstitute the hematopoietic system of a lethally irradiated mouse as efficiently
as WT cells. The higher proliferative profile of SHIP-/- HSC should have given
them an advantage in the reconstitution assay. Therefore, we had to further
investigate why SHIP-/- HSC are not able to accomplish long-term reconstitution.

SHIP-/- HSC Have a Lower Rate of Spontaneous Apoptosis

It was reported that SHIP-/- mice have increased osteoporosis caused by
an increase in osteoclast activity.101

The HSC niche is dependent on the

presence of osteoblasts, the counter part of osteoclasts, to properly sustain the
hematopoietic compartment.132

Thus, any disruption of the balance between

osteoblasts and osteoclasts could destroy the niche necessary for HSC survival,
resulting in anoikis-associated apoptosis of the HSC compartment. If SHIP-/HSC exhibited increased apoptosis, this could contribute to the decreased ability
of SHIP-/- HSC to accomplish long-term repopulation. Therefore, we assessed
the level of apoptosis in SHIP-deficient HSC and we found that a significantly
lower proportion of SHIP-/- HSC were apoptotic relative to WT HSC as measured
by Annexin V staining (Figure 12A). In fact, 11.1% of WT HSC (KTLSFlk2-)
stained with Annexin V while only 1.1% of SHIP-/- HSC did. TUNEL analysis
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done on SHIPΔIP/ΔIP HSC also revealed that SHIP-deficient HSC were undergoing
apoptosis at half the rate of WT HSC in the BM (Figure 12B). Thus, the lack of
long-term repopulating activity of SHIP-/- HSC activity appears not to be
associated with anoikis-induced apoptosis of the compartment.

Figure 12. SHIP-/- HSC exhibit decreased apoptotic rate. (A) Representative FACS
plots of DAPI vs. Annexin V after gating on KTLSFlk2- cells. Bar graph shows the
percentage of KTLSFlk2- that are apoptotic based on the Annexin V+ and DAPI- staining,
SHIP-/- (black); WT (grey). (B) Representative FACS plots for TUNEL staining after
gating on KTLS cells. Bar graph represents the percentage of KTLS cells positive for
TUNEL staining, SHIP-/- (black); WT (grey). Data acquired using FACS Aria, DiVaII
software and analysis done with FlowJo.

Significance was established using the

unpaired student t test (Prism 4): *p<0.01 and ++p<0.005. (mean ± SEM, n≥3).
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In vivo Homing of SHIP-/- Stem/Progenitors to the BM is Significantly Reduced as
Compared to WT

We considered that the diminished repopulation observed for SHIP-/- HSC
could result from an inefficiency of SHIP-/- HSC to home and be retained in the
BM niche. Thus, we assessed the homing capacity of SHIP-/- stem/progenitor
cells compared to WT cells in an in vivo homing assay.147,175 Sca1+Lin- cells from
the BM of SHIP-/- and WT mice were isolated, stained with fluorescent dyes, and
The frequency of SHIP-/- and WT

injected into irradiated recipient mice.

Sca1+Lin- cells present in the recipient BM and spleen was later assessed by
flow cytometry (Figure 13A). Using a total of 12 recipients for each genotype, we
found that SHIP-/- stem/progenitor cells reached the BM with a significantly
reduced

efficiency

relative

to

WT

stem/progenitor

cells

(Figure

13B).

Furthermore, we observed that SHIP-/- Sca1+Lin- cells did not home to the spleen
as well as WT Sca1+Lin- cells (Figure 13C). These results suggest that SHIP-/HSC are impaired in their ability to home and be retained in hematopoietic
organs. This deficiency likely contributes to their inability to engraft and sustain
multi-lineage hematopoiesis.
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Figure 13. SHIP-/- Sca1+Lin- cells do not home to the BM as efficiently as WT Sca1+Lin-.
(A) Representative FACS plot of BM from
transplant recipients after gating on live
cells. (I) Shows BM from control recipient
12-14

hours

after

transplantation

with

0.5x106 WBM stained with 1 μM DDAO .
(II) Shows BM from control recipient 12-14
hours after transplantation with 0.5x106
WBM stained with 0.5 μM CFSE. (III)
Representative FACS plot of BM from a
mouse 12-14 hours after transplantation
with 2x105 SHIP-/- Lin-Sca1+ cells stained
with 0.5 μM CFSE and 2x105 WT Lin-Sca1+
cells stained with 1 μM DDAO. (B) Left:
Percentage of dye+ SHIP-/- (black) or WT
(grey) Sca1+Lin- cells found in the recipient
BM 12-14 hours after transplantation. Right:
Percentage of SHIP-/- (black) or WT (grey)
Sca1+Lin- cells that trafficked to and was
retained in BM of recipients over the total
number of cells injected, 12-14 hours after
transplantation.
stained
+

-/-

SHIP

(C) Left: Percentage of
(black)

or

WT

(grey)

-

Sca1 Lin cells found in the spleen of recipients 12-14 hours after transplantation. Right:
Percentage of SHIP-/- (black) or WT (grey) Sca1+Lin-cells that reached the spleen of
recipients over the total number of cells injected, 12-14 hours after transplantation. Data
acquired using FACS ARIA, DiVaII and analysis done with FlowJo. Significance was
established using the stratified Wilcoxon-Mann Whitney test using StatXact (Cytel
Software Corporation, Cambridge, MA, USA): +p<0.05, *p<0.01 and ++p<0.005. (mean
± SEM, n=12).
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Reduced Surface Expression of CXCR4 and VCAM-1+ on KTLS Cells in SHIP-/BM

CXCR4, VCAM-1 and VLA-4 are all known to play prominent roles in
homing and trafficking of HSC and other hematopoietic cells to BM.151,158,176
Thus, we decided to examine the level of expression of these markers on SHIP-/HSC cells compared to WT HSC. By flow cytometry, we observed a 2.5-fold
reduction in the surface expression of the CXCR4 receptor on SHIP-/- KTLS
relative to WT KTLS (Figure 14A, B).

Flow cytometry analysis showed a

reduction in VCAM-1 surface expression on SHIP-/- HSC cells as compared to
WT HSC (Figure 14A). We found that 22.1±2.5% of SHIP-/- KTLS were positive
for VCAM-1 while 50.8±6.9% of WT KTLS were (Figure 14A, B). The VCAM-1
MFI values for SHIP-/- KTLS were also reduced by 3-fold as compared to WT
KTLS (Figure 14B). However, not all homing molecules showed a reduced level
of expression. For example, the percentage of KTLS cells expressing VLA-4 as
well as their MFI values in SHIP-/- BM cells were unchanged compared to WT
BM. Furthermore, contrary to SHIP-/- KTLS, SHIP-/- Lin+c-Kit- and Lin-c-Kit+ cells
did not exhibit a significant difference in the level of VCAM-1 and CXCR4
expression as compared to WT Lin+c-Kit- cells (Figure 15). We also observed
the level of VCAM-1 and CXCR4 expression in the KLS and KLSThy1populations to evaluate if SHIP deficiency impacted the expression of these
markers in different progenitor population or only in the HSC enriched KTLS
population. We observed that the reduction in CXCR-4 expression is specific to
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the KTLS population (Figure 14). The KLS population, which contains HSC and
mostly early and late progenitor cells did not exhibit a significant difference in
their ability to express CXCR4 in the absence of SHIP as compared to WT
controls (Figure 16Bi-Ci). Furthermore, we observed no significant difference in
the level of CXCR4 expression by SHIP-/- KLSThy1- cells as compared to WT
control (Figure 17Bi-Ci). However, percentage of VCAM-1+ KTL (Figure 16Cii)
and KLSThy1- (Figure 17Cii) were both reduced by 2-fold in SHIP-/- mice BM as
compared to WT control. These results suggest that SHIP might impact VCAM-1
expression in different cell types, including KTLS (Figure 14), KLS (Figure 16),
and KLSThy1- cells (Figure 17), while SHIP appears to affect CXCR4 expression
mostly in KTLS cells (Figure 14 - 17). Interestingly, the late progenitor cells (lincKit+) and differentiated cells (Lin+cKit-) (Figure 15) in SHIP-/- mice had a
comparable level of CXCR4 and VCAM-1 expression as compared to WT.
Reduction of VCAM-1 and CXCR4 expression on the SHIP-/- HSC suggests
these cells may be hampered in their ability to traffic and be retained in the BM,
consistent with the decreased BM homing and retention we observe (Figure 13).
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Figure 14. SHIP-/- HSC express lower levels of CXCR4 and VCAM-1 molecules as
assessed by flow cytometry. (A) A representative histogram of CXCR4 (left) and VCAM1 (right) expression on live (DAPI-) KTLS cells (isotype control (light grey), SHIP-/(black), and WT (grey)). (B) The plots on the left represent the mean fluorescence
intensity (MFI) of KTLS cells for CXCR4, VCAM-1, and VLA-4, respectively and the plots
on the right show the percentage of KTLS cells positive for VCAM-1 and VLA-4,
respectively (SHIP-/- (square); WT (triangle)). Data acquired using FACS ARIA, DiVaII
and analysis done with FlowJo. Significance was established using the unpaired student
t test (Prism 4): +++p<0.0005 and +p<0.05. (mean ± SEM, n≥3).
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Figure 15. SHIP-/- late progenitor and differentiated cells express the same levels of
homing molecules as assessed by flow cytometry. (A) A representative histogram of
CXCR4 (left) and VCAM-1 (right) expression on live (DAPI-) Lin+c-Kit- (isotype control
(light grey), SHIP-/- (black), and WT (grey)). (B) The plots on the left represent the mean
fluorescence intensity (MFI) of Lin-c-Kit+ (top) and Lin+c-Kit- (bottom) cells for CXCR4,
VCAM-1, and VLA-4, and the plots on the right show the percentage of Lin-c-Kit+ (top)
and Lin+c-Kit- (bottom) cells positive for CXCR4, VCAM-1 and VLA-4. (SHIP-/- (black);
WT (grey)). Data acquired using FACS ARIA, DiVaII and analysis done with FlowJo.
Statistical analysis was done using the unpaired student t test (Prism 4). (mean ± SEM,
n≥3).

53

Figure 16. SHIP-/- early progenitors express the same levels of CXCR4 and have a
reduced percentage of VCAM-1+ cells. (A) FACS plot representing gating strategy for
the analysis of CXCR4 and VCAM-1 expression on KLS cells for (i) SHIP-/- and (ii) WT
BM cells. (B) A representative histogram of CXCR4 (i) and VCAM-1 (ii) expression on
live (DAPI-) Lin-c-Kit+Sca1+ (isotype control (light grey), SHIP-/- (black), and WT (grey)).
(C) (i) Bar graphs representing the percentage and MFI of Lin-c-Kit+Sca1+ cells for
CXCR4 expression. (ii)

Bar graphs representing the percentage and MFI of Lin-c-

Kit+Sca1+ cells for VCAM-1 expression. Data acquired using FACS ARIA, DiVaII and
analysis done with FlowJo. Statistical analysis was done using the unpaired student t
test (Prism 4). (mean ± SEM, n≥3).
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Figure 17. SHIP-/- early progenitors express the same levels of CXCR4 and have a
reduced percentage of VCAM-1+ cells. (A) FACS plot representing gating strategy for
the analysis of CXCR4 and VCAM-1 expression on KLSThy1- cells for (i) SHIP-/- and (ii)
WT BM cells. (B) A representative histogram of CXCR4 (i) and VCAM-1 (ii) expression
on live (DAPI-) Lin-c-Kit+Sca1+Thy1- (KLSThy1-) (isotype control (light grey), SHIP-/P

(black), and WT (grey)). (C) (i) Bar graphs representing the percentage and MFI of Linc-Kit+Sca1+ cells for CXCR4 expression. (ii) Bar graphs representing the percentage
and MFI of KLSThy1- cells for VCAM-1 expression. Data acquired using FACS ARIA,
DiVaII and analysis done with FlowJo. Statistical analysis was done using the unpaired
student t test (Prism 4). (mean ± SEM, n≥3).
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Elevated Levels of Soluble VCAM-1 Levels in SHIP-/- Mice Sera

Interestingly, we observed that SHIP-/- mice sera contained an increased
level of soluble VCAM-1 (sVCAM-1) (Figure 18). This molecule once released in
the circulation through proteolytic cleavage remains active and can still bind VLA4 receptor.177,178 Thus, sVCAM-1 has the potential to hinder the interaction of
leukocyte and HSC with endothelium.179,180 Therefore, elevated sVCAM-1 could
potentially bind VLA-4 receptor on HSC and prevent its interaction with
endothelium-bound VCAM-1 and prevent its homing to the BM. This particular
scenario could in part explain why we see an increase in HSC number in the
periphery and maybe why we see a decrease in the homing properties of these
cells. One theory for the latter hypothesis would be that sVCAM1 bind the VLA-4
receptor, preventing their interaction with membrane-bound VCAM-1.

Figure 18. sVCAM-1 levels are significantly increased
in SHIP-/- sera as compared to WT littermates. Blood
was obtained by sub-mandibular bleed and collected in
regular Eppendorf tube to allow coagulation. The sera
was then collected and sent for analysis by ELISA
(Charles River Laboratories Inc.).

ELISA was then

performed to assess the level of different cytokines.
Significance was established using the unpaired student t test (Prism 4): ++p<0.005
(mean ± SEM, n≥3). Collaboration with D. Woods and WG Kerr Ph.D.
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Discussion

In this study, we show that SHIP-/- mice had increased HSC in their BM,
spleen and PB than WT littermates based on analysis using multiple HSC
phenotypes. An expansion of the HSC compartment was also observed in a
second SHIP-deficient model, in which the inositol phosphatase region was
targeted, the SHIPΔIP/ΔIP.97 This latter model is deficient for SHIP expression and,
presumably s-SHIP expression, contrary to the SHIP-/- model.

s-SHIP is an

isoform expressed in ES cells and HSC but not in differentiated cells.49 Our
studies show that SHIPΔIP/ΔIP HSC have a similar phenotype to the SHIP-/- HSC
as compared to WT showing an expansion of the HSC compartment, decreased
apoptosis rate and decreased level of CXCR4 expression.

According to our

data, the ablation of both isoforms did not result in a more severe HSC
phenotype. However, additional studies should be done to further assess the
role of s-SHIP in this cell type.

The increase in HSC numbers observed in SHIP-deficient mice may partly
result from the increased proliferation and decreased apoptotic frequency
observed in the SHIP-/- HSC compartment. These results are consistent with
SHIP being a negative regulator of several signaling pathways downstream of
receptors that impact HSC proliferation and survival, such as c-mpl, IL-3R,
CXCR4, Flt3 and c-Kit, which induce cell proliferation and/or survival through
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activation of the MAPK and PI3K/Akt pathways.15,25,47,181-187 Moreover, SHIP-/myeloid and hematopoietic progenitor cells are hyper-responsive to several of
these factors.18 The enhanced survival and proliferation of SHIP-/- HSC could
partially explain the decreased repopulating ability of these cells as it was shown
that cycling HSC engraft less efficiently than resting HSC.146,165,167

Homing and eventual engraftment of HSC following transplantation has
been shown to rely on the expression and activity of several surface molecules,
including VLA-4, VLA-5 and CXCR4.151,188,189 The CXCR4 receptor induces cell
migration towards an increasing gradient of SDF-1/CXCL12.149

Treatment of

NOD/SCID mice with SDF-1 leads to the mobilization of HSC to PB150 and
treatment of human HSC with anti-CXCR4 antibody prior to transplantation in
NOD/SCID mice results in HSC engraftment failure.151 Furthermore, CXCR4 and
SDF-1-deficient mice are embryonic lethal since HSC fail to migrate from the FL
to the BM, where definitive hematopoiesis would take place. In addition, one of
the ligands for VLA-4, VCAM-1, which is usually found on stromal/endothelial
cells, has been shown to be expressed in hematopoietic cells such as Mac-1+,
B220+ and, more interestingly, c-Kit+ cells.158 Even though the role of VCAM-1
on hematopoietic stem/progenitor cells remains to be fully elucidated, there is
evidence that it is involved in their retention in the BM, as shown for B cell
progenitors.158 With that information in mind, the reduction in the percentage of
HSC expressing CXCR4 and VCAM-1 receptors in SHIP-/- BM can provide a
basis for the decrease in SHIP-/- HSC ability to home to the BM, as shown by our
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in vivo homing assays (Figure 13). This inefficiency of SHIP-/- HSC to reach and
be retained in the HSC niche could contribute to their impaired self-renewal and
long-term repopulating capacity.

In previous studies, in vitro stimulation of

murine BM stem/progenitor cells with different cytokines was shown to induce
cell cycle, decrease VLA-4 expression and compromise engraftment.146 In our
study, the increase in HSC cell cycle observed in vivo did not necessarily
correlate with a decrease in VLA-4 expression, but caused a decline in long-term
engraftment capacity.

We observed that decreased CXCR4 and VCAM-1

expression on KTLS cells correlated with a reduction in the homing process.
Moreover, CXCR4 has been shown to participate in the activation of VLA-4 and
VLA-5 to promote human HSC attachment and extravasation, resulting in homing
of HSC to the BM niche.189 The reduction in the CXCR4 receptor seen on SHIP-/HSC might also dampen this process and, thus, HSC homing. Furthermore, it
has been shown that CXCR4 and VCAM-1 are important for the retention of HSC
or hematopoietic progenitors in the BM.157,158 Interestingly, we find that SHIP-/mice have an increased number of HSC cells in their spleen (Table 1 and Figure
5A, B) and peripheral blood (data not shown), consistent with the down
modulation of CXCR4 and VCAM-1 on SHIP-/- HSC. On the other hand, the
increased level of sVCAM-1 in the plasma of SHIP-/- mice could hinder the
interaction between HSC and endothelium and dampen the homing and retention
process of these cells.
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Even though we observed a reduction in engraftment by both the DC and
CRU assay, the defect seems greater in the DC assay, where equal numbers of
purified SHIP-/- and WT HSC are co-transplanted. This suggests that in the CRU
assay, where WBM cells are used, the increased number of HSC in SHIP-/- BM
might partially compensate for the reduced levels of CXCR4 and VCAM-1 on
SHIP-/- HSC, resulting in better engraftment by SHIP-/- HSC in the CRU assay as
compared to the DC assay.

The CRU assay included in this study showed a decrease in the
repopulating ability of SHIP-/- WBM, while previous studies revealed that SHIP-/WBM had comparable repopulating activity in a limiting-dilution CRU assay.156
The different results observed between the two CRUs might stem from the
variation in the assays themselves.

In the Harrison CRU assay, healthy

competitor cells are utilized, while the limiting-dilution CRU assay requires the
use of competitor WBM weakened by two serial transplantations.190 Thus, the
compromised WBM competitors in the latter CRU assay may be unable to
compete for the niche as efficiently as normal WT WBM against SHIP-/- WBM.
Furthermore, the calculation method for the Harrison CRU assay differs from the
one used for the limiting-dilution assay, which might result in a different
assessment of repopulating activity by the two assays.

In summary, our findings demonstrate a role for SHIP in the maintenance
of the HSC compartment. SHIP appears to be critical for the negative control of
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HSC proliferation and survival as well as impacting the ability of HSC to home
and be retained in the BM niche.

Materials and Methods

Mice

SHIP-/- mice were generated by deletion of the promoter and first exon of
SHIP via a Cre-loxP strategy and then backcrossed to the C57BL6/J
background.43 SHIPΔIP/ΔIP mice were created using a Cre-loxP strategy targeting
P

the inositol phosphatase encoding region.

SHIPΔIP/ΔIP mice are on a 129SvJ

background and were kindly provided by Dr. Jeffrey Ravetch (Rockefeller
University, NY, USA).97 For all experiments, germline SHIP-deficient and WT
mice were 6-8 weeks of age. For the inducible model, SHIP fl/fl mice were
backcrossed to MxCre germline. The resulting SHIP fl/fl MxCre+ and MxCremice were treated 3 times with 625 μg polyIC in the course of 7 days. At least 20
days after the last treatment, the mice were sacrificed and experiment was
performed. As recipients for transplantation experiments we used 8-12 weeks
old B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) (Jackson Laboratory Bar Harbor,
Maine, USA) and a CD45.1xCD45.2 strain generated by intercrossing C57BL6/J
(CD45.2) and B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) mice. Animal experiments
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were conducted in compliance with institutional guidelines at the University of
South Florida.

Cell Isolation

BM cells were flushed from intact femurs and tibia. Splenocytes were
isolated by crushing the spleen with a syringe plunger. All cells were collected in
tissue media (TM) composed of RPMI, 3% fetal bovine serum (FBS), and 10mM
HEPES (Gibco BRL/Invitrogen, Carlsbad, CA, USA). Cells were then filtered
through a 70μm strainer (BD Biosciences, San Jose, CA) and red blood cells
(RBC) were lysed at room temperature (RT) for 2-5 minutes in 1xRBC lysis buffer
(eBioscience, San Diego, Ca, USA). The remaining cells were then centrifuged
and resuspended in staining media (SM) composed of 1xDulbecco-Phosphate
buffered saline (D-PBS), 3% FBS, and 10mM HEPES (Gibco BRL/Invitrogen).
PB was obtained by retro-orbital (RO) or sub-mandibular bleeding, collected in
microtainers with K2EDTA (BD, Franklin Lakes, NJ, USA), and RBC lysed twice
to obtain PB mononuclear cells (PBMC), which were resuspended in SM.

HSC Phenotype

All antibodies were from BD Biosciences except where noted. All flow
cytometry data were analyzed with FlowJo Software (Tree Star, Inc. Ashland,
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OR, USA). BM cells, splenocytes or PBMC were treated with Fc block (2.4G2)
and then stained on ice for Lineage-/lowc-Kit+Sca1+Thy1+ (KTLS) phenotype.159
The stain included, Sca1-PE (E13-161.7), c-Kit-APC (2B8), Thy1.2-Cychrome
(53-1.2) and a lineage (Lin) panel-FITC: CD2(RM2-5), CD3ε (145-2C11),
CD4(GK1.5), CD5(53-7.3), CD8α(53-6.7), B220(RA3-6B2), Gr-1(RB6-8C5), Mac1(M1/70), NK1.1(PK136), and Ter119(TER-119) (eBioscience).

For Lin-c-

kit+Sca1+CD48-CD150+ (KLSCD48-CD150+),162 the same Lin panel was used
with the addition of CD34–FITC (RAM34) along with Sca1-biotin (E13-161.7), cKit-APCCy7 (2B8) (eBioscience), CD48-PE (HM48-1), CD150-Alexa647 (9D1)
(Serotec Inc., Raleigh, NC, USA), followed with streptavidin-PeCy7. The cells
were then resuspended in SM containing 75ng/ml of 4',6-diamidino-2phenylindole dihydrochloride (DAPI) for dead cell exclusion (Sigma-Aldrich,
St.Louis, MO, USA). Analysis was done on a FACS Vantage or FACS Aria using
DiVaII software (BD Biosciences).

For the c-Kit+Flk2-Lin-/lowSca1+ (KFLS)

phenotype,160 we used Sca1-FITC, c-Kit-APC and the above mentioned Lin
panel-PE with the addition of the Flk2 antibody (A2F.10-1). After staining, the
cells were washed and resuspended in SM containing 7-amino-actinomycin D (7AAD) (BD Biosciences) for dead cell exclusion. Acquisition was done on a FACS
Calibur with CellQuest software (BD Biosciences). For the side population (SP)
analysis, BM cells were stained following standard procedure.163 Analysis was
done on a FACS Vantage using DiVaII. For the analysis of Mac 1 expression on
KTLS, the same Lin panel (FITC) as the one defined above was used with the
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exception of Mac1. The same antibody clones as the one mentioned above were
used, but they were conjugated to different fluorochromes: Sca1-PE, c-KitPeCy7, Thy-APC, Ma1-ApcCy7. DAPI was used for dead cell exclusion and the
data acquired on FACS Aria with DiVaII software.

For homing marker analysis, Lin-depletion of BM cells was done on the
AutoMACS (Miltenyi Biotec) using the Lin-PE panel described above, with the
exclusion of CD2, anti-PE magnetic beads (Miltenyi Biotec). The Lin-depleted
fraction was stained for KTLS and CXCR4 (2B11/CXCR4), VCAM-1 (429), or
VLA-4 (9C10) on biotin, followed by staining with streptavidin-PeCy7. DAPI was
used for dead cell exclusion. Data was acquired on a FACS Aria using DiVaII.

Cell Cycle Analysis

BM cells were enriched either for Sca1+ or c-Kit+ cells using AutoMACS
(Miltenyi Biotec). Sca1+ or c-Kit+ cells were then stained for the KTLS or KFLS,
then fixed in Cytofix/Cytoperm solution (BD Biosciences) for 30-min on ice,
washed in Perm/Wash buffer and incubated with 4-10ng/ml Hoechst dye 33342
(Sigma-Aldrich) in Perm/Wash buffer overnight at 4oC. The DNA content was
measured 24-hrs later on the FACS Vantage and analyzed using FlowJo
software.
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CRU Assay

CD45.1 recipient mice were given antibiotic water -- sulfamethaxazole and
trimethorprim oral suspension 40mg/ml (Hi-Tech Pharmacal CO., INC. Amityville,
NY, USA) prior to receiving a single dose of 9.5-Gy 3-hours before
transplantation. One million WBM cells from CD45.2 SHIP-/- or WT mice along
with 1x106 CD45.1 WBM cells were injected retro-orbitally into recipients, as per
Harrison.169

Transplanted mice were later assessed for PB multi-lineage

reconstitution. Repopulating units (RU) were calculated as per Harrison et al.:169
RU = (10 * CD45.2 repopulation(%))/(100 – CD45.2 repopulation(%)).169

DC Assay

The DC assay was modified from Domen et al.173 Donor BM cells were
magnetically enriched for Sca1+ cells on AutoMACS (Miltenyi Biotec). The Sca1+
fraction was stained for Lin-/lowc-Kit+Sca1+Thy1low or Lin-/lowFlk2-c-Kit+Sca1+ and
sorted twice in the presence of DAPI using the FACS Vantage DiVAII. For the
KTLS transplantation, 200 CD45.1 WT and 200 CD45.2 SHIP-/- KTLS cells were
injected with 4x104 Sca1- CD45.1/45.2 WBM cells. For the KFLS transplantation,
100 CD45.1 WT and 100 CD45.2 SHIP-/- KFLS cells were injected with 4x105
CD45.1/45.2 Sca1- cells. CD45.1/45.2 recipients had been previously irradiated
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with a split dose of 10Gy at 3-hour interval and given antibiotic water, as
mentioned above.

Assessment of Multi-Lineage Reconstitution

For the first 4 months after transplantation the level of PB reconstitution
was assessed, every 4 weeks, as a measure of engraftment of SHIP-/- and WT
HSC. PBMC were treated with Fc block, then stained with CD45.1-PE(A20),
CD45.2-FITC (104), and APC-conjugated Lin markers; B220, CD3, or Mac1/Gr1
(clones as previously mentioned). The cells were then washed and resuspended
in SM containing 7-AAD to exclude dead cells. Data acquired on FACSCalibur
with CellQuest and analyzed with FlowJo. To assess the level of reconstitution
of differentiated cells in the BM, spleen and PB 6 to 8 months after
transplantation, we used the same antibody clones mentioned above except that
Mac1 was conjugated to APCCy7 and Gr1 to APC. Furthermore, DAPI was used
for dead cell exclusion and data was acquired on a FACSAria using DiVaII
software. To assess the level of KTLS reconstitution, BM cells were enriched for
Sca1 on the AutoMACS (Miltenyi Biotec) using the Sca1-Biotin and anti-biotin
magnetic beads (Miltenyi Biotec). Sca1+ cells were then stained for Lin-FITC,
Sca1-biotin, c-Kit-APCCy7, Thy1-APC, CD45.1-PE and CD45.2-PerCPCy5.5.
The Sca1-biotin was revealed using Streptavidin-PeCy7. DAPI was used for
dead cell exclusion. Data was acquired on FACS Vantage with DiVaII software.
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Annexin V Assay and TUNEL Assay

BM cells were isolated stained with c-Kit-APCCy7, Thy1.2-APC, Lin-FITC,
Sca1-Biotin and Flk2-PE on ice, biotin was revealed by streptavidin-PeCy7. The
cells were then incubated with Annexin V (BD Biosciences) according to the
manufacturer’s protocol. Analysis was done on a FACSAria using DAPI for dead
cell exclusion.

TUNEL assay was performed using the In situ cell death

detection Kit following manufacturer’s instruction (Roche Applied Science,
Indianapolis, IN, USA). First, BM cells were depleted of Lin+ cells using Lin-PE,
anti-PE beads, and the autoMACS (Miltenyi Biotec), Lin- cells were then stained
for KTLS and TUNEL.

In Vivo Homing Assay

Homing assays were optimized from previous protocols.147,175 BM cells
from 6-8 week old SHIP-/- and WT mice were isolated from hind/fore limbs and
from vertebral column.

BM cells were then RBC lysed, Fc blocked for 15

minutes, then depleted of Lin+ cells using Lin-PE, followed by anti-PE beads,
using autoMACS (Miltenyi Biotec). Lin- cells were then stained for Lin-PE, Sca1FITC and DAPI and Sca1+Lin- cells were sorted on the FACS Aria. After sorting,
the cells were stained with 1μM of 9-H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-
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yl) phosphate (DDAO-SE) (Molecular Probe/Invitrogen, Carlsbad, CA, USA)
and/or 0.5 μM carboxyfluoroscein succinimidyl ester (CFSE) (Molecular
Probe/Invitrogen) for 15 minutes at 37oC, washed and centrifuged at 300xg for 7
minutes at 4oC. Cells were then resuspended in PBS with 1mM HEPES and an
equal number of live Sca1+Lin- SHIP-/- and WT cells (2x105 cells of each
genotype) were then injected into irradiated recipient mice (1000 rads 3 hours
prior to transplantation). For some experiments, both CFSE stained SHIP-/- and
WT Sca1+Lin- cells were injected in different recipients. In others, CFSE stained
SHIP-/- and DDAO stained WT Sca1+Lin- were injected in the same recipients.
Twelve to 14 hours after injection, BM cells and splenocytes were isolated from
recipients and directly analyzed on a FACS Aria in the presence of DAPI. Five
million events were collected for each recipient.

Measurement Cytokines and Growth Factors Levels in Mice Sera

Blood was obtained by sub-mandibular bleed, collected in a regular
Eppendorf tube and left at RT for 4 hours to allow coagulation. The blood was
then stored at 4oC overnight. The following day, blood clots were removed using
a wooden stick and the remaining blood was centrifuged at 4000 RPM for 10
minutes at 4oC. The sera was then isolated by taking the supernatant and sent
for analysis at a custom based service at Charles Rivers Laboratories Inc., where
ELISA for multiple cytokines and growth factors was performed.
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Section II: Influence of SHIP on Megakaryocytes and Megakaryocyte Progenitors

Introduction
Megakaryocytes

Platelets are responsible for repair of vascular damages, wound repair,
innate immune response, and metastatic tumor cell biology.191 In human, 1 x
1011 platelets are produced each day in order to maintain proper balance, and
during time of crisis, this number can increase up to 10 fold.192

Mature

megakaryocytes (MK) that are responsible for the production of platelets arise
from the differentiation and maturation of megakaryocyte progenitors (MKP). In
turn, MKP are derived from early myeloid progenitors, which also give rise to
granulocytes/monocytes and erythrocytes (Figure 4).

The different stages of

MKP differentiation, from MKP proliferation to platelet shedding, and the diverse
cytokines influencing that process, are depicted in Figure 19.

From early

progenitor proliferation, MKP maturation to platelet shedding by MK, the
megakaryocyte lineage has a unique way to control its homeostasis, mainly
through chemokines, growth factors, and cytokines.193-196;

197-210

As it is shown

on Figure 19, some cytokines are more important for the early development or
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proliferation of MKP, such as IL-3 and c-KitL, while others, including IL-6 and
mostly TPO impact MK maturation and platelet release. One major component
of MK maturation is the process of endomitosis, which generates MK that have
an average DNA content of 32N, and exhibit an increase in cell size, mRNA
content, and protein production.211,212

After fragmentation of polyploid MK,

approximately 3000 platelets are generated,213 all of which are small cells that
lack a nucleus, but have a highly organized cytoskeleton, the major necessary
components to control thrombosis; unique receptors and specialized secretory
granules.214,215 The level of platelet in an organism must be tightly regulated to
prevent blood clot due to unwarranted production of platelet or excessive
bleeding caused by a decrease in platelets levels.
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Figure 19.

Megakaryocytopoiesis and cytokines that influence the process.

The

different steps of megakaryocytopoiesis are influenced by many cytokines in vitro and in
vivo.216,217

While the in vivo deletion of IL-3, IL-6, IL-11 and LIF does not affect

megakaryocyte development, knockout mouse model for SF, TPO, and its receptor Mpl
exhibit a megakaryocyte development defect. Interestingly, treatment of Tpo-/- and Mpl-/mice with FGF-4 and SDF-1 induced platelet production to levels comparable to WT.200
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The Involvement of SHIP in MK Signaling Pathway

Early on many cytokines, including IL-3, IL-6, IL-11, LIF, c-KitL, Epo and
G-CSF

have

been

thrombopoiesis.193-197

shown

to

impact

megakaryocytopoiesis

and

It was shown that they can influence megakaryocyte

progenitor (MKP) proliferation and differentiation, in vitro, in a synergistic manner,
none of them being sufficient to promote megakaryocytopoiesis alone. However,
it was always believed that megakaryocytopoiesis was controlled by a major
growth factor that still had to be discovered. Even though the cytokine TPO was
not physically isolated before 1994, the word thrombopoietin was first used in
1958 to describe a factor that would stimulate platelet production in mice and
human.201-203

In 1994, several groups identified and cloned the humoral factor primarily
responsible for MKP and MK proliferation and maturation.204,205,209 These groups
identified TPO, as a molecule that can bind to c-mpl,204,205,209 a cellular protooncogene from a human erythroid leukemia cell line with strong homology to vmpl, murine myeloproliferative leukemia virus oncogene.218,219 Administration of
TPO leads to a strong enhancement of MKP/MK proliferation, maturation and
polyploidization,205,207,210 as well as a dramatic increase in platelet numbers.208
TPO is constitutively produced by kidney and liver, and the control of its
production appears not to be at the mRNA levels but to depend on platelet
numbers.220

One of the major mechanism by which TPO regulates
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megakaryocytopoiesis appears to be based on the level of free (unbound) TPO
available in the blood,221 such that free TPO levels in the blood are inversely
proportional to the amount of platelets.222 If platelets levels are high, most of the
TPO is bound to platelets, leading to a decrease in the megakaryocytopoiesis
process. As levels of free TPO increase in the blood after injury or platelet insult,
the megakaryocytopoiesis process is induced in order to replace the lost
platelets.

TPO was initially thought to be a lineage specific cytokine that induces
megakaryocytopoiesis in vivo and in vitro. However, TPO is now known to have
an important role in the biology of several other hematopoietic cell types such as
erythrocytes,223-225 granulocytes/macrophage,223-225 neutrophils-colony forming
cells (CFC),225 and hematopoietic stem/progenitor cells.184,225-227 Although TPO
is the primary regulator for megakaryocytopoiesis, it has been shown that c-mpl
and TPO deficient mice still have a reduced level of functional platelets, their
numbers being 85% that of WT mice.206,228 This suggests that other factors can
impact megakaryocytopoiesis independently of TPO. It was demonstrated by
several groups that SDF-1 can impact thrombopoiesis and in combination with
other chemokines can compensate for TPO deficiency.198,199,205,229,230 In fact,
SDF-1 and FGF-4 have recently been shown to have the capacity to palliate TPO
deficiency.200 Simultaneous administration of SDF-1 and FGF-4 to Tpo-/- and cmpl-/- mice, through an adenoviral system, led to a recovery of platelet numbers
similar to the one observed in WT mice.200 It appears that these chemokines are
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important for the interaction of MK with sinusoidal BM endothelial cells,
promoting their maturation and platelet shedding.198,200 It was also shown that
SDF-1 induces transendothelial MK migration and platelet production in vitro199
and in vivo.230 Moreover, SDF-1 appears to enhance human thrombopoiesis in
xenotransplanted NOD/SCID mice.231

Interestingly, it was shown that SHIP

might impact signaling pathways downstream of SDF-1.27,152 In that study, the
authors observed that CXCR4 engagement by its ligand SDF-1, led to
phosphorylation and recruitment of Shp-2. In this cell context, Shp-2 was found
in a protein complex including the proteins SHIP, cbl, and fyn.27 Furthermore,
SHIP-deficient myeloid progenitors exhibit enhanced chemotaxis towards SDF1.152

When TPO binds to c-mpl, it induces phosphorylation and/or activation of
an array of signaling molecules including proteins in the JAK/STAT pathway,
STAT3, STAT5, Shc, Lyn, SHIP and PI3K.191,232-236 In that cell context, PI3K
converts PI(,4,5)P2 to PI(3,4,5)P3, the latter can then recruit PH domain containing
proteins, leading to Akt activation, increased cell survival and proliferation of
MK.235

Interestingly, TPO activation of PI3K in mature platelets result in

enhanced α-granule secretion and thrombin induced aggregation activation.237

SHIP has been shown to oppose PI3K signaling by removing the 5’
phosphate of PI(3,4,5)P3,2,3,5 and to be phosphorylated following c-mpl
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engagement by TPO in mature MK and c-mpl transfected BA/F3 cells.235
Therefore, SHIP could block this key signaling pathway downstream of the c-mpl
receptor

152,238

On the other hand, engagement of c-mpl by TPO leads to Shc

phosphorylation and association with Grb2/SOS, resulting in the promotion of
Ras activation of the MAPK pathways.24,239,240 Knowing that SHIP can compete
with Grb2 for binding to Shc, SHIP could negatively control the MAPK pathway
activation.1 Furthermore, other cytokines that have been shown to play a role in
megakaryocytopoiesis are known to stimulate or to depend on SHIP for the
dampening of their signaling pathways, including IL-3, c-KitL, and GCSF.3,13,22,216,241,242

Interestingly,

Lyn-/-

mice

exhibit

an

increase

in

megakaryocytopoiesis.243,244 Lyn kinase is a negative regulator of cell signaling
pathways downstream of receptors for different cytokines including M-CSF and
TPO.45,236 Lyn is known to phosphorylate and recruit SHIP to the membrane
after cytokine stimulation of the cells. Since SHIP is important for the negative
control of several signaling pathways downstream of cytokines implicated in
megakaryocytopoiesis, we hypothesize that SHIP-deficient mice might show an
increase in megakaryocytopoiesis and thrombopoiesis.
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Aims:

1) Assess the level of MK and MKP in SHIP-/- mice hematopoietic organs by flow
cytometry as compare to WT mice.
2) Attempt to identify the factors responsible for the perturbation of the MK
compartment.

Results

MKP are Increased in the BM and Spleen of SHIP-Deficient Mice

We analyzed BM, spleen and PB from SHIP-/-, SHIPΔIP/ΔIP, and their
respective WT littermates to determine the size of the MKP compartment in vivo
by flow cytometry (Figure 20A), using an immunophenotype defined by Hodohara
and colleagues,245 Lin-c-Kit+CD41+, which contains the majority of CFU-Mk
activity. We observed an expansion of the MKP compartment in the BM of SHIP/-

and SHIPΔIP/ΔIP mice as compared to their WT littermates (Figure 20BI). In fact,

SHIP-/- and SHIPΔIP/ΔIP BM showed a mean 18.1-fold and 50-fold increase,
respectively, in the absolute number of MKP relative to WT controls (Figure
20BI). However, the numbers of MK, as defined by the immunophenotype Lin-cKit-CD41+, were decreased by a mean 2-fold in SHIP-/- and SHIPΔIP/ΔIP BM as
P

compared to WT control (Figure 20CI).
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Figure 20. Increased number of MKP in SHIP-deficient BM. (A) Flow cytometry analysis
of BM, spleen, and PB from SHIP-/- (-/-) and SHIPΔIP/ΔIP (ΔIP/ΔIP) and WT littermates.
Representative flow cytometry plot of c-Kit vs. CD41 after gating on live cells and Lincells.

MKP are in the upper right quadrant and MK in the lower right quadrant.

Percentages for each population are indicated on the plot. (B) Bar graph showing the
absolute numbers of MKP (Lin-c-Kit+CD41+) cells in (I) BM (sum of 2 femurs + 2 tibias),
(II) whole spleen and (III) per μl of PB. (C) Bar graph showing the absolute numbers of
MK (Lin-c-Kit+) cells in (I) BM (sum of 2 femurs + 2 tibias), (II) whole spleen and (III) per
μl of PB.

Bar graphs showing the different SHIP-deficient models (black) and their

respective WT littermates (gray).

Data acquired using FACS Calibur, CellQuest

software and analysis done with FlowJo.

Significance was established using the

unpaired student t test (Prism 4): ***p<0.0001, +++p<0.0005, ++p<0.005, and +p<0.05.
(mean ± SEM, n≥3). Collaboration with N. Parquet and LE Perez MD.

77

The observation of splenocytes for the presence of MKP and MK by flow
cytometry (Figure 20A, Bii, Cii) revealed that SHIP-/- and SHIPΔIP/ΔIP spleens
exhibited higher percentages of MKP and MK as compared to WT littermates
(data not shown). The absolute number of splenic MKP was increased by at
least 30-fold in both, SHIP-/- and SHIPΔIP/ΔIP mice, as compared to their respective
WT littermates (Figure 20BII). Furthermore, the absolute number of splenic MK
was increased by a mean 10.9-fold in SHIP-/- spleen as compared to WT
littermates (Figure 20CII).

SHIPΔIP/ΔIP mice exhibited an even more dramatic

increase in the absolute number of splenic MK as compared to WT control
(Figure 20Cii).

Analysis of PB for the presence of MK and MKP by flow

cytometry revealed that it contains very few MKP, with an average of 3 to 5
MKP/μl.

Using this method, we observed that the number of MKP was not

significantly increased in SHIP-/- mice when compared to WT (Figure 20BIII).
However, MKP numbers were slightly, but significantly higher, in SHIPΔIP/ΔIP PB
as compared to WT littermates (Figure 20BIII). Furthermore, in the PB of SHIP-/mice there was a mean 7.7-fold increase in the absolute number of MK and the
same trend was observed for SHIPΔIP/ΔIP mice (Figure 20CIII).

We then combined the number of MKP and MK present in the BM and
spleen in SHIP-deficient mice as compared to WT controls (Figure 21). In both,
the SHIP-/- and SHIPΔIP/ΔIP mice, the total MKP numbers were increased by a
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mean 3.5-fold as compared to their respective WT littermates (Figure 21A).
Despite an increase in total MKP numbers in SHIP-deficient mice, we observed
that these mice have a comparable total number of MK as compared to WT
littermates (Figure 21B). Thus, the decrease in MK numbers observed in SHIPdeficient BM (Figure 20Bi) is compensated for by the increase in splenic MK
numbers (Figure 20Ci).

This results in SHIP-deficient mice containing a

comparable number of total MK as compared to WT littermates.

Figure 21. Total MKP but not total MK numbers are increased in SHIP-deficient mice
are compared to WT. The total number of MKP and MK was calculated by adding the
absolute number MKP or MK in the spleen and
whole BM of one mouse.

To calculate the

number of MKP and MK in the whole BM of a
mouse, multiply the number of MKP or MK in one
femur by a 16.6.156 (A) Total absolute number of
MKP in the spleen and whole BM of SHIPdeficient mice and their WT littermates. (B) Total
absolute number of MK in the spleen and whole
BM of SHIP-deficient mice and their WT
littermates. Data acquired using FACS Calibur,
CellQuest software and analysis done with
FlowJo.

Significance was established using the unpaired student t test (Prism 4):

+++p<0.0005 and ++p<0.005. (mean ± SEM, n≥3).
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MKP and MK are Increased in BM and Spleen of SHIP-Ablated Mice

To observe if inhibition of SHIP during adulthood could also result in an
increase in MKP production, we used the MxCre model. This model is described
in the previous section on SHIP and HSC. Briefly, the treatment of MxCRE+fl/fl
mice with polyIC will lead to Cre recombinase expression through Type
interferon-inducible Mx1 promoter, and deletion of the gene section between two
loxP sites. In this case, the promoter and the first exon of the SHIP gene will be
deleted resulting in the ablation of SHIP expression. As control, MxCre-/SHIPfl/fl
are treated with polyIC in the same manner than the MxCRE+fl/fl mice. Twentyone days after the last polyIC treatment, mice were euthanatized and the level of
MKP was evaluated by flow cytometry (Figure 22Ai). As observed in Figure 19Bi
we see an increase in the percentage of MKP in the BM and spleen of SHIPablated mice as compared to MxCre- mice. Furthermore, we observe that SHIPablated BM contains approximately 4 times more MKP than their MxCrecounterpart (Figure 22Bii).

As for the germline SHIP-/-, we also observe an

increase in the percentage of MK present in the spleen (Figure 22Biii). This
result suggests that mice that undergo normal development can also exhibit
increased MKP numbers once SHIP is deleted during adulthood. This has some
therapeutic implication, where SHIP inhibition could be used to increase in
megakaryocytopoiesis in adult patients.
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Figure 22. Significant increase in the percentage of MKP cells in SHIP-ablated BM and
spleen. MxCre+ and MxCre- mice with floxed SHIP alleles were treated with polyIC 3
times prior to being analyzed. (A) Representative FACS plots showing detection of and
MK and MKP in the BM and spleen of MxCre+ and MxCre- mice after treatment. (B) (i)
Percentage of MKP in BM (top), spleen (Spl) (bottom) and of SHIP-ablated (black) and
WT (grey) mice. (ii) Absolute number of MKP cells in BM (per femur and tibia pair). (iii)
Percentage of MK found in the spleen. Data acquired on a FACS Calibur with CellQuest
software (BD Biosciences, San Jose, CA), analyzed with FlowJo.

Significance was

established using the unpaired student t test (Prism 4). +++p<0.0005, ++ p<0.005, and
+p<0.05. (mean ± SEM, n≥3).
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Platelet Levels are Lower in SHIP-Deficient Mice as Compared to WT Mice

One striking observation is that despite the profound expansion of the
MKP in SHIP-/- and SHIPΔIP/ΔIP mice, these mice do not exhibit increased platelet
levels relative to WT controls, when measured by hematolyzer (Table 2). The
analysis of SHIP-/- and SHIPΔIP/ΔIP PB revealed that these mice have a significant
reduction in their platelet as compared to WT littermates (Table 2). Furthermore,
SHIP-/- as well as SHIPΔIP/ΔIP mice PB have a significantly lower percentage of
hematocrit. SHIP heterozygous mice platelet and hematocrit levels were not
significantly different than the WT levels.

The hematocrit percentages and

platelet counts observed in PB isolated from SHIP heterozygous mice were not
significantly different than the one observed for the WT PB (Table 2) all p values
being above 0.5. Except for SHIP+/- PB hematocrit percentage (p=0.072), all
heterozygous values shown in Table 2 were significantly difference than the
values observed for their respective SHIP-deficient PB.
Table 2. Platelet and Hematocrit counts in SHIP-deficient mice.
Mice genotype
SHIP-/SHIP+/SHIP+/+ (C57Bl6)

Platelet levels (#x103/μl)

Hematocrit (%)

672.8 ± 43.4++
848.9 ± 35.7
803.7 ± 31.5

42.5 ± 1.4+
45.2 ± 0.5
46.6 ± 0.5

455.4 ± 81.1++
43.1 ± 1.4++
SHIPΔIP/ΔIP
652.3 ± 28.0
46.8 ± 0.5
SHIP+/ΔIP
+/+
SHIP (129SvJ)
647.9 ± 28.0
47.0 ± 0.6
+
p < 0.05 compared to their respective WT littermates
++
p < 0.05 compared to their respective WT and SHIP heterozygous littermates
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SHIP-Deficient MK are Morphologically Different than WT MK

BM histopathology revealed that MK in SHIP-/- BM have a hypolobulated
micromegakaryocytic morphology when compared to WT BM, which contains
mature hyperlobulated MK (Figure 23A). The increase in MK numbers found by
flow cytometry in the SHIP-deficient spleens was corroborated by morphology,
where the spleens of SHIP-deficient mice have a qualitative increase in the
number of MK (Figure 23B). These observations suggest a shift in the site of
megakaryocytopoiesis from the BM to the spleen. This is in agreement with
other findings suggesting that the spleen of SHIP-deficient mice becomes the site
of intense extramedullar hematopoiesis.95,156,246

Figure 23. Hematoxylin-eosin
staining of SHIP-deficient WT
BM

and

spleen.

(A)

Hematoxylin-eosin staining of
SHIP-/- and WT BM section,
photographed

at

63x.

(B)

Hematoxylin-eosin staining of
SHIPΔIP/ΔIP and WT spleen
section,

the

images

were

photographed at 40x (spleen).
Cells were visualized on a
Leica DM LB microscope. Pictures were taken using a RTcolor Spot camera (Diagnostic
Instrument Inc) with Spot Advance v3.0 software. Collaboration with N. Parquet and
L.E. Perez MD.
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Comparable Ploidy Distribution in SHIP-/- MK as Compared to WT

The hypolobulated micromegakaryocytic morphology of SHIP-/- BM MK
cells observed by histology suggested that these cells did not mature properly.
Therefore, we evaluated the ploidy distribution in BM and splenic SHIP-/- MK, as
endomitosis is an obligatory step towards MK maturation.

However, these

results revealed that SHIP-/- BM and splenic MK cells have a similar ploidy
distribution than WT MK (Figure 24). Thus, SHIP-/- Lin-CD41+ cells do exhibit a
similar ploidy distribution, thus have a comparable ability to undergo
endoreplication as compared to WT Lin-CD41+ cells (Figure 24A, B).
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Figure 24. SHIP-/- MK undergo endocytosis with the same efficiency as WT MK. BM
cells and splenocytes from SHIP-/- and WT mice were enriched for CD41+ on
P

AutoMACS, stained with Lin-panel and CD41-biotin/SA-APC, fixed/permeated and
stained with PI in the presence of RNase. (A) Representative gating strategy to obtain
the final FACS plot used to calculate the DNA content of Lin-CD41+ cells.

(B)

Representative FACS plot used to calculate the DNA content of BM and spleen LinCD41+ cells for SHIP-/- and WT. (Ci) Bar graph representing the percentage of BM LinCD41+ cells in the different ploidy stage visible on the plot.

(Cii) Bar graph with

emphasis on the higher ploidy distribution for BM Lin-CD41+ cells.
-

(Di) Bar graph

+

representing the percentage of spleen Lin CD41 cells in the different ploidy stage visible
on the plot. (Dii) Bar graph focusing on the higher ploidy distribution for spleen LinCD41+ cells

Data acquired using FACS LSR, DiVaII (BD Biosciences).

Statistical

analysis was done using the unpaired student t test (Prism 4). (mean ± SEM, n≥3).
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TPO Levels are Increased in SHIP-/- Plasma as Compared to WT

It has been proposed that SHIP might contribute in the control of pathways
downstream of c-mpl, and the lack of SHIP could result in a higher response to
TPO stimulation as compared to WT littermates. However, an increase in sera
TPO levels could also result in increased megakaryocytopoiesis. Therefore, we
assessed the level of TPO in SHIP-/- mice sera. Consistent with the decreased
platelet levels (Table 2) and the increased megakaryocytopoiesis (Figure 20)
observed in SHIP-/- mice, we saw that SHIP-/- sera contained a significantly
higher concentration of TPO as compared to WT mice. ELISA performed on
SHIP-/- and WT sera revealed that SHIP-/- sera had a concentration of 12.8 ± 0.2
ng/ml of TPO while WT had 11.67 ± 0.2 ng/ml (Figure 25A). Although this is only
a difference of 1.2 ng/ml, it is statistically significant according to an unpaired
student t test (p<0.005) (Figure 25A). Furthermore, IL-6, a cytokine that has
been shown to impact early megakaryocytopoiesis216 and TPO production during
inflammation,247 was increased in SHIP-/- mice sera as compared to WT (Figure
25B), this was also observed in another SHIP knock-out model at the mRNA
level.

However, not all factors shown to impact megakaryocytopoiesis were

increased in SHIP-/- mice as shown in Figure 25C, LIF levels in SHIP-/- mice were
not significantly different from WT mice. The increase in IL-6 and TPO observed
in SHIP-/- sera could contribute to the increase in megakaryocytopoiesis
observed in these mice.
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Figure 25. TPO levels are significantly increased in SHIP-/- sera as compared to WT
littermates. Mice were bled by sub-mandibular bleeding and the blood was collected in
regular Eppendorf tube to allow coagulation. The sera was then collected and sent for
analysis by ELISA (Charles River Laboratories Inc.).

(A)

Levels of TPO in SHIP-/-

(square) and WT (triangle) sera. (B) Levels of IL-6 in SHIP-/- (square) and WT (triangle)
sera. (C) Levels of LIF in SHIP-/- (square) and WT (triangle) sera. Significance was
established using the unpaired student t test (Prism 4). ++ p<0.005 (mean ± SEM,
n≥3). Collaboration with D. Woods and WG Kerr Ph.D.
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Discussion

The ablation of SHIP results in an augmentation of MKP production.
However, we observe that the total number of MK in SHIP-deficient mice is
comparable to the one observed in WT. The decrease number of MK in the BM
of SHIP-deficient mice appears to be compensated for by a dramatic increase in
splenic MK. Therefore, there are some indications that in SHIP-deficient mice
the mature MK leave the BM prematurely to be found in the periphery, in the
spleen and PB. The shift in MK localization from the BM to the periphery might
result from an increased responsiveness to SDF-1, which can cause transendothelial migration of MK from the BM to the circulation.198-200 Thus, SHIP may
participate in the control of pathways downstream of CXCR4 mediating MK
migration, as it does in myeloid progenitors.152

Alternatively, the increase in

peripheral MK might result from extramedullar hematopoiesis as it was shown
that

SHIP-deficient

spleen

contain

elevated

levels

of

HSC156,246

and

hematopoietic progenitors (Figure 21B).95

We observe that MK cells in the BM of SHIP-deficient mice are
hypolobulated and less mature than the one found in WT BM by looking at
morphology (Figure 23). This would suggest that SHIP-deficient BM MK cells do
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not mature properly. However, we observed that BM, like splenic, SHIP-/- MK
exhibited a comparable ploidy distribution as the one seen for WT MK cells. This
result suggests that the SHIP-deficient BM MK mature as well as WT BM MK.
Alternatively, SHIP-/- MK might exit the BM prematurely, before the shedding of
platelets, as they might be more responsive to SDF-1 induced migration
signaling.

Platelet levels limit megakaryocytopoiesis by sequestering TPO.216 These
platelets have c-mpl receptors on their surface that can bind TPO molecules.248
Therefore, it has been suggested that the level of free-TPO in circulation is
inversely proportional to platelet levels.249 Thus, a decrease in platelet levels
would cause an increase in free-TPO and stimulate megakaryocytopoiesis in
order to replenish the platelet stock. In SHIP-deficient mice, we observed a
significant decrease in platelet levels and, consequently, a significant increase in
TPO levels as compared to WT controls.

The increase in free-TPO might

stimulate the proliferation and/or survival of MKP in SHIP-deficient mice, leading
to an expansion of the megakaryocytic compartment.

Furthermore, SHIP-

deficient MKP could be hyper-responsive to the free-TPO available since it was
shown previously that SHIP is phosphorylated after c-mpl engagement with TPO
in primary MK and c-mpl transfected Ba/F3 cells.235. Administration of TPO to
patients or test animals causes the increase in platelet levels only a few days, 3
to 5, after treatment.250

This suggests that TPO does not regulate directly

release of platelet but mainly the proliferation and maturation of MKP and MK
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respectively. Thus, the increase in MKP numbers but not in platelet levels in
SHIP-/- mice might further suggest that megakaryocytopoiesis and platelet
shedding are regulated by different mechanisms.

Furthermore, it is worth noting that SHIP has been shown to be present in
human platelets and to be responsible for the production of PI(3,4)P2 during
aggregation dependent activation of platelets. PI(3,4)P2 in human platelets was
shown to mediate actin assembly for filopodial growth,251 and sustained exposure
of integrin GpIIB-IIa leading to irreversible aggregation.251-253 This process is
probably hindered in SHIP-deficient platelet since it is responsible for removing
the 5’ phosphate of PI(3,4,5)P3, to create PI(3,4)P2. Thus, SHIP-deficient platelet
might have compromised function, affecting their activation status and causing
premature elimination from the circulation.

As mentioned earlier, we observe a significant decrease in the mean
platelet numbers in SHIP-/- mice as compared to WT mice. This could in part
explain the increase in TPO levels observed in these mice. However, researches
have shown that inflammation can contribute to increasing TPO production.247
Actually, cytokines produced by monocytes, including macrophages, can induce
a chain reaction, involving an increase in IL-6 levels, promoting increased
production of TPO by the liver.191,247 SHIP-/- mice have increased number of
macrophages in their BM, spleen and periphery,95 and we observe that these
mice exhibit significantly higher IL-6 levels (Figure 25B). In fact, we observed
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that SHIP-/- mice have 49 pg/ml of IL-6 in their sera as compared to 1 pg/ml for
WT (Figure 25B).

This increase IL-6 sera concentration could induce TPO

production by the liver

Furthermore, we observe that both SHIP-deficient models exhibit a
decrease in hematocrits as compared to their respective WT (Table 2).
Helgason et al reported that F2 SHIP-/- mice (129 mice backcrossed twice to
C57Bl6 mice) have no difference in hematocrit levels compared to WT.
However, a more recent publication reveals that F6-7 SHIP-/- mice exhibit a
significant decrease in hematocrit levels as compared to WT.254 In this later
paper, it was mentioned that the increased severity of the erythroid defect might
result from backcrossing onto C57Bl6 strain.

However, since the SHIP ΔIP/ΔIP

mice are on a mixed background, this explanation seems unlikely. Looking back
at the data published in 1998, there was already a great difference in the
percentage of hematocrits between WT and SHIP-deficient mice with 50.7±1.0%
for WT versus 42.4±5.7 for SHIP-deficient mice. However the standard error
mean was large for SHIP-deficient mice, probably caused by a small sample
population.95 In the second study, they seem to have used a larger sample
group,254 which could have helped reduce the standard error mean, and show a
significant difference between the two sample groups.
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Our results suggest that SHIP negatively controls pathways promoting
early megakaryocytopoiesis. However, the fact that we observe a similar level of
MK in SHIP-/- and WT mice suggests that different pathways control MKP
proliferation, MK maturation and platelet shedding. On the other hand, SHIPdeficient MK could leave the BM prematurely due to increased responsiveness to
SDF-1, which could hamper MK maturation and the platelet shedding process.

These findings suggest that SHIP could be targeted in vivo to increase the
pool of MKP, and subsequently enable this compartment to replenish platelets
more rapidly following myeloablative chemotherapy and radiation treatment.
However, this assumes that SHIP deficiency does not adversely impact MK
maturation, platelet shedding from MK or platelet function.

Materials and Methods
Mice Strains

SHIP-/- mice (F9 or F10 X C57BL6/J) produced in our laboratory have a
deletion of the SHIP promoter and first exon.43 A second SHIP-deficient mouse
model was also analyzed, SHIPΔIP/ΔIP (129SvJ),97 in which the inositol
phosphatase domain is deleted was kindly provided by Dr. Jeffrey Ravetch,
Rockefeller University, NY, USA. All studies described herein were conducted
on six to eight week-old adult mice. For the inducible model, SHIP fl/fl mice were
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backcrossed to MxCre germline. The resulting MxCre+fl/fl and MxCre-fl/fl mice
were treated 3 times with 625 μg polyIC in the course of 7 days. Mice were
analyzed at least 21 days after the last injection. Experiments were performed in
compliance with institutional guidelines of the University of South Florida.

Cell Isolation

Isolation of BM cells and splenocytes was as described previously.246
Following red blood cell (RBC) lysis, the cells were resuspended in staining
media..246

PB was obtained from the retro-orbital sinus, sub-mandibular bleed

or heart puncture. For MKP analysis of PB, RBC were lysed twice in 1x RBC
lysis buffer (eBioscience). Cells were then resuspended for antibody staining.

Flow Cytometry Analysis and Antibodies

Staining of MKP and MK was performed as per Hodohara et al245 All
antibodies were from BD Biosciences except when mentioned otherwise. The
cells were treated with anti-CD16/CD32 (2.4G2) to block Fc receptors and then
stained with a Lin panel-PE, CD41-FITC(MWReg30), and c-Kit-APC(2B8). The
Lin- panel was CD3ε(17A2), CD4(GK1.5), CD8α(53-6.7), B220(RA3-6B2), Gr1(RB6-8C5), Mac-1 (M1/70) (Caltag, Burlingame, CA) and Ter119(TER-119).
Dead cells were excluded using 7-AAD (BD Biociences). Data was acquired on
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a FACS Calibur using the FACS Quest software and analysis was done using
FlowJo 4.5.

Platelet Analysis

Blood was collected by heart puncture or sub-mandibular bleed and
platelets were quantified using the CellDyn 3700 hematology analyzer (Abbott
Diagnostic, Dallas, Texas USA).

Histopathology

Bone and spleen were fixed in 10% buffered paraformaldehyde. Bone
were first decalcified using Routine Acid Decalcification (RDO; Apex engineering
Products, Plainfield, IL, USA), followed by sectioning.

The spleen and bone

sections were then stained with hematoxylin-eosin after being deparaffinized with
xylene. Briefly, slides were stained using the modified Meyer’s hematoxylin and
eosin phloxine B solution (Fisher Scientific, Suwanee, GA, USA) according to a
modified Armed Forces Institute of Pathology (AFIP) protocol.

Cells were

visualized on a Leica DM LB microscope. Pictures were taken using a RTcolor
Spot camera (Diagnostic Instrument Inc) with Spot Advance v3.0 software.
Ploidy assay
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BM cells were isolated from hind/fore limb and vertebral column. Briefly,
cells were incubated with CD41-biotin antibody (Serotec, Raleigh, NC, USA) on
ice and then with anti-biotin beads (Miltenyi Biotec) at 4oC. CD41+ cells were
then selected using the autoMACS (Miltenyi Biotec). Collected CD41+ cells were
stained with Lin panel-FITC as mentioned above and with streptavidin-APC (BD
Biosciences). The cells were fixed in 1% formaldehyde (Sigma-Aldrich) for 15
minutes on ice and then incubated overnight in a 70% ethanol solution at -20oC.
The day after, the cells were washed carefully of any residual ethanol with PBS
and incubated for at least 3 hours in a propidium iodine (PI) solution composed of
50 μg/ml PI, 0.1% Triton X-100, 2.5U/ml RNase in PBS without Ca or MG (all
from Sigma-Aldrich except for the PBS which was from Gibco BRL/Invitrogen).

Measurement of Cytokines and Growth Factors Levels in the Sera of
Experimental Mice

Blood was obtained by sub-mandibular bleed, collected in a regular
Eppendorf tube and left at RT for 4 hours to allow coagulation. The blood was
then stored at 4oC overnight. The following day, blood clots were removed using
a wooden stick and the remaining blood was centrifuged at 4000 RPM for 10
minutes at 4oC. The sera was then isolated by taking the supernatant and sent
for analysis at a custom based service at Charles Rivers Laboratories Inc., where
ELISA for multiple cytokines and growth factors was performed.
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Section III: Natural Killer Cells and SHIP

Introduction to Natural Killer Cells

NK cells were first defined as a cell fraction residing in the spleen, with the
ability to spontaneously kill tumor cells without prior immunization.255-257
However, it is now known that NK cells are found in the BM, liver and PB. NK
cells are derived from the same progenitor cell as T-lymphocytes, either the
common lymphocyte progenitor in BM or the NK-T cell precursor in fetal liver.258
Although common in origin key difference do exist between the two cell types.
One primordial distinction is that NK cells do not undergo the maturation process
that T-cells go through in the thymus and are unable to accomplish gene
rearrangement for the production of antigen specific receptors.259 Furthermore,
NK cells are part of innate immunity, and the first line of defense of an organism
against viral infection and tumorigenic transformation of host cells.255-257 These
cells can kill target cells either by direct cell-mediated cytotoxicity or by secretion
of soluble factors. To this effect they can produce diverse cytokines, such as IL5, IL-10, IL-13 and GM-CSF.260

However, NK cells secrete predominantly

interferon-γ (IFN-γ), which helps control tumor cell proliferation and kill virally
infected cells.261,262 In fact, it was shown that NK cells store IFN-γ transcripts,263
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which can be rapidly released upon stimulation. They also express molecules
member of the Tumor necrosis factor (TNF) family such as, TNFα, Fas ligand
(FasL) and TNF related apoptosis inducing ligand (TRAIL), which bind to death
domain-containing receptors on target cells causing their apoptosis.264,265 Most
importantly, NK cells contain granules storing perforin and granzyme,266-268 all of
which can be secreted shortly after stimulation. For example, perforin dependent
cytotoxicity can be mediated within 20 minutes after activation of NK cells.269
Thus, as soon as these cells encounter a potential target, they are ready for
action. It is therefore suited that NK cells be tightly regulated by an array of
receptors that trigger activation and inhibitory response depending on the target
cell and cytokines present.270 This fine balance between inhibition and activation
prevents inadvertent killing of normal healthy host cells.

Activation of NK cells by engagement of activating receptors leads to the
stimulation of kinases that triggers cytolysis of target cell. The whole process
remains to be further elucidated, but to date we know that several molecule
become phosphorylated or recruited during NK cells activation, including Syk,271
SLP-76,272 ZAP-70,273 Linker for activation of T cell (LAT),274 Shc,275 PI3K,276,277
PLCγ1 and 2.278-280 Interestingly, it was observed that NK cells ablated for Syk
and ZAP-70 can develop normally and lyse tumor cells in vitro and in vivo.281
Thus, these molecules are used for activation of NK cells but are not essential.
On the other hand, simultaneous inhibition of PI3K and Src kinases prevented
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the cytolytic activity of these mutant NK cells and strongly reduced that of WT NK
cells, suggesting that distinct and redundant signaling pathways act in a
synergistic manner to trigger cytotoxicity.281

To this end, PI3K is known to

mediate the production of PI(3,4,5)P3, which lead to calcium increase and
activation of PLCγ molecules. PLCγ-2 ablated NK cells were shown to be greatly
reduced in their ability to lyse target cells and secrete IFN-γ in response to
stimulation of signaling pathways mediated by DNAX adapter protein-10 (DAP10), which contains an ITAM motif.279 Furthermore, PLCγ-2 ablated NK cells
have a disrupted receptor repertoire, particularly for Ly49 receptors.279

NK Cell Receptors

As mentioned above NK cell cytotoxic activity is regulated by a fine
balance between activating and inhibitory receptors. The inhibitory receptors
expressed by NK cells are many and differ in structure and ligand specificity.
These receptors are encoded in a defined region on chromosome 6 that was
named “the NK cell gene complex”.282 This chromosomal region encodes for
series of receptor molecules that can form disulfide–bound homodimers,
characterized by being type II integral membrane proteins with C-type lectin
domains. The NK cell gene complex encode for the activation receptor such as
CD69283 and for members of the Nkrp1 (NKR-P1A, B, C) multigene family.282,284
Nkrp1-C, also called NK1.1, and part the of the Nkrp1 family285 is expressed on
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NK cell and a subset of T cells, and even though its ligand is unknown it is
believed that NK1.1 is an activation molecule since antibody cross-linking leads
to activation of NK cells and lysis of target cells.286 Most importantly for this
work, the NK cell gene complex encodes for members of the Ly49 receptor
family, which is composed of at least 23 members (Ly49A through W) (Table
3).287 The ligands for 14 of these receptors are known so far (Table 3).287
Table 3. Functions and ligands of Ly49 NK cell receptors
Receptor
Function
Cellular
Viral ligand
name
Ligands
b
Ly49A
Inhibitory
D , Dd, Dp, Dk
Ly49B
Inhibitory
?
Ly49C
Inhibitory
Kb, Kd, Kk, Dd, Db
Ly49D
Activating Dd
Ly49E
Inhibitory
?
Ly49F
Inhibitory
Dd
Ly49G
Inhibitory
Dd, Ld
MCMV-m157
Ly49H
Activating Db
Ly49I
Inhibitory
Kd
MCMV-m158
b
Ly49J
Inhibitory
K
Ly49K*
Activating ?
Ly49L
Activating Kk
Ly49M
Activating ?
Ly49N*
Activating ?
Ly49O
Inhibitory
Db, Dd, Dk, Ld
Ly49P
Activating Dd
Ly49Q
Inhibitory
?
Ly49R
Activating Dd, Dk, Ld
Ly49S
Inhibitory
?
Ly49T
Inhibitory
?
Ly49U
Activating ?
Ly49V
Inhibitory
Db, Dd, Kk
Ly49W
Activating Dd, Kk
* To date no full length transcript have been found
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These receptors are disulfide–bound homodimers, type II trans-membrane
proteins with C-type lectin-like domains. Ten of these appear to be activating
receptors, of which some bind MCH class I molecules while others recognize
MHC–like molecules produced by viruses. For example Ly49H recognizes m157
molecules produced by murine cytomegalovirus infected cells.288,289

Ly49

activating receptors contain no ITIM motif and do not seem to become
phosphorylated upon engagement with ligand.

Instead they necessitate the

interaction with ITAM-containing adapter molecule to exert their effect, such as
death adapter protein 12 (DAP12),290 CD3ζ,291 DAP10,292,293 and FcεRIγ,294 the
latter being responsible for binding to CD16 and stimulate antibody-dependent
cellular cytotoxicity (ADCC).295 DAP12 is a 16kDa protein with an aspartic acid
residue in its transmembrane region, which can interact with the asparagine on
Ly49D transmembrane region upon its engagement.296

After this interaction,

tyrosine in the ITAM of DAP12 becomes phosphorylated,297 which leads to a
activation of signaling events involving the phosphorylation of Syk, PLCy-1 and
calcium mobilization.290,296 It was also shown that the SH2 domain of Syk can
interact with DAP12 phosphorylated tyrosine.296,297

The activation and/or

phosphorylation of these effector molecules will lead to the release of perforin,
granzyme and cytokines to kill the target cell and stimulate a complete immune
response.
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The activation of NK cells has to be counterbalanced by inhibitory
signaling in order to prevent inadvertent attack of host cells. To this effect, NK
cells rely on the presence of inhibitory receptors that recognize MHC class I
molecules on host’s cells such as receptors of the Ly49 receptors family. The
inhibitory receptor Ly49A was the first one to be cloned from the NK cell gene
complex.298 The human counter part of the Ly49 inhibitory receptors are the
killer cell inhibitory receptors (KIRs), which belong to the Ig superfamily.299 KIRs
and Ly49 receptors evolved separately into totally different molecules that both
have the ability to negatively control NK cell activation through recognition of
MHC Class I molecules.

Furthermore, they both exhibit a cytoplasmic ITIM

sequence, and both were observed to associate with Shp-1 and/or Shp-2 after
engagement, leading to inhibitory signaling.300,301

Like human KIRs, murine Ly49 receptors such as Ly49 A, C, G2 and I,
have a cytoplasmic ITIM motif that becomes tyrosine-phosphorylated upon
engagement by self MHC class I molecules.302-304 The murine ITIM sequence
was first identified as a 13 amino acid sequence on FcγRIIB receptor necessary
for inhibitory function.305,306

ITIMs are now know to be present in several

receptors involved in immunological processes and are usually composed of 6
amino acids (I/V/L/S)-X-Y-X-X-(L/V).307

Upon engagement of inhibitory

receptors, such as Ly49A and G2, the tyrosine residue in the ITIM becomes
phosphorylated and can then recruit molecules that contain a SH2 domain such
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as Shp-1308 and possibly Shp-2.309 Once activated, these molecules can then
dephosphorylate and therefore deactivate Syk, PLCγ-1/2, ZAP70, and Shc, which
would participate in the stimulation of cytotoxic response.310 These inhibitory
receptors are responsible for preventing unwanted attack against host cells,
however, once an infected or cancerous cells down-regulate expression of their
MHC class I molecule, Ly49 inhibitory receptors can not be engaged and NK
cells are then free to kill. This process was first described by Karre and his
colleagues, who observed that an H-2B deficient lymphoma was rejected by the
host, while a lymphoma that expressed MHC molecules would engraft in the
host. They named this concept the “missing-self hypothesis” (Figure 26).311 It
was later confirmed by other groups who noticed that β2-microglobulin deficient
cells would get rejected by irradiated MHC-matched mice while β2-microglobulin
expressing cells could engraft successfully.312,313 These studies relate that NK
cells will be inhibited from killing a possible target cell when this one expresses
the right MHC molecules. The MHC molecules bind inhibitory receptors on NK
cells, which then block activation pathway.
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Figure 26. Missing-self hypothesis. Graphic representation of the possible outcomes
when a NK cell encounters a possible target cell. MHC class 1 or non-MHC class I
molecules expressed by the host can be recognized by inhibitory receptors on NK cells,
dampening the possible response of NK cells. The level of activation and inhibitory
signal received by the NK cell, and the qualitative difference in the signal transduced will
determine the NK cell response.

Loosely adapted from Lanier review on NK cells

published in 2005.314
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SHIP and NK Cell Development

The transcriptional regulation of Ly49 receptors remains to be fully
elucidated. Why is their expression variegated? Why do certain subset of NK
cells in the same individual express different but overlapping Ly49 receptors on
their surface? Right before the proliferation phase, immature NK cells, which
already express NK1.1 and the CD122 (IL-2 and IL-15 receptor β) receptor,
acquire CD94-NKG2 and Ly49 receptors.315

Thus, it is possible that upon

acquisition of the Ly49 receptors, the cell subset that bear Ly49 engaged by the
host MHC Class I molecules would be prompt to survive or proliferate. To this
end, the Ly49 receptors specific for the host MHC molecule would guide the
proliferation and survival of the NK cell subset that expresses it. Consistent with
this hypothesis, the p85 subunit of PI3K can be recruited to the membrane by
inhibitory Ly49 receptors to promote formation of PI(3,4,5)P3. Even though that
molecule has been implicated in the simulation of NK cells through activation of
PLCy, it is possible that PI(3,4,5)P3 recruit the PH containing protein AKT, which
will promote survival and proliferation of the cell. Since SHIP contains an SH2
domain, it could be recruited to the membrane by Ly49 receptor phosphorylated
ITIM motifs, where it would negatively control the survival and/or proliferation
signal received by NK cells through dephosphorylation of PI(3,4,5)P3. This event
would prevent over-representation of a certain subset of receptors, thus,
maintaining a proper repertoire of Ly49 receptor on NK cells.
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Aims::
1) Define the NK cell compartment in SHIP-/- mice.
2) Identify factors contributing to the disruption of NK cell receptor repertoire.

Results

Spleen of SHIP-/- Have Increased Number of NK Cells

Analysis of the NK compartment in the spleen at different stages of
ontogeny indicated that NK cells develop normally in juvenile SHIP-/- mice (Figure
27Ai, B). However, in SHIP-/- adult mice an abnormal population of NK cells
appears that exhibit a 10-fold increase in the surface expression level of the NK
receptor, NK1.1 (NK1.1hi), as compared to WT controls (Figure 27Aii, Aiii). The
NK1.1hi population lacks CD3 and thus is not an NK-T cell population.

The

appearance of the NK1.1hi population coupled with an increase in NK cells with a
normal 2B4+NK1.1+ staining profile (NK1.1+ cells) leads to a 2 to 3-fold increase
in peripheral NK cells in SHIP-/- adult mice (≥8 weeks), relative to wild-type
littermates (Figure 27B).
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Figure 27. Increased NK cell numbers in SHIP-/-. (A) FACS analysis of splenic NK cells
in SHIP+/+ and SHIP-/- littermates at different stage of ontogeny, at (i) 3, (ii) 5, and (iii) 8
weeks.

Genotype and age of the mice at the time of sacrifice and analysis are

indicated.. (B) Absolute splenic NK cell numbers in SHIP+/+ and SHIP-/- mice at
different ages. Significance was established using the unpaired student t test (Prism 4).
(mean ± SEM, n≥3).

The values determined for SHIP-/- mice that are significantly

different from that of their age-matched SHIP+/+ counterparts are indicated by the
following symbols: +p<0.05 and,* p<0.01. Collaboration with J. Howsen, T. Ghansah
Ph.D., S. May and K.HT Paraiso MS.
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Murine NK cells detect MHC class I molecules using receptors encoded
by the Ly49 or CD94/NKG2 genes.316 Expression of these MHC receptors is
distributed among different NK subsets during the transition from neonate to
adult.

Because the number of peripheral NK cells increases in SHIP-/- mice

during this period, we asked whether the relative representation of NK subsets
expressing certain Ly49 and CD94 receptors might account for this increase.
Indeed, the relative representation of several Ly49 receptors and CD94 was
significantly altered in the SHIP-/- NK compartment of older mice when compared
to SHIP+/+ littermates (Figure 28). However, SHIP-/- weanlings, at 3 weeks of
age, showed no skewing of their NK repertoire relative to wild-type littermates
(Figure 28).

The NK cell receptor repertoire distortion was most pronounced in mice ≥8
weeks of age and was found in both the NK1.1+ and the NK1.1hi populations. We
found that Ly49A+ and C/I+ NK cells were overrepresented in adult SHIP-/- mice,
while Ly49D+, G2+ and CD94+ were underrepresented (Figure 28). Because the
overwhelming majority of the NK1.1+ and NK1.1hi cell populations lacked Ly49I in
adult SHIP-/- mice, the majority of the Ly49C/I+ NK cells express only Ly49C.
Thus, the repertoire distortion in adult SHIP-/- mice leads to an NK compartment
dominated by a subset of cells expressing Ly49A and/or Ly49C, where Ly49D,
G2, I can CD94 are underrepresented (Figure 28). In vitro and in vivo studies
indicated that Ly49A and Ly49C can bind ligands in the H2b haplotype of SHIP-/107

mice; however, these two receptors also bind and transmit inhibitory signals from
ligands in most or all H2 haplotypes.317-320 Therefore, SHIP deficiency leads to
an NK inhibitory repertoire that is both, self-specific and promiscuous for other
ligands.

A potential explanation for the repertoire disruption seen in SHIP-/- NK
cells is that SHIP is recruited to certain inhibitory receptors expressed by NK cells
to oppose intracellular signals that mediate survival of specific NK subsets
expressing these receptors. Indeed, SHIP binds the phosphorylated ITIM motif of
Ly49A in vitro.42 These findings prompted us to examine whether SHIP
associates in vivo with Ly49 receptors expressed by NK cells.
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Figure 28. MHC class I receptors on peripheral NK cells in SHIP-/- mice. The mean
percentage of peripheral NK cells expressing the indicated Ly49 or CD94 molecule after
gating on 2B4+NK1.1+ cells. The age and genotype of the mice are indicated.
Significance was established using the unpaired student t test (Prism 4). (mean ± SEM,
n≥3). Values determined for SHIP-/- mice that are significantly different from their agematched SHIP+/+ littermates are indicated: +p<0.05; * p<0.01. Collaboration with J.
Howsen, T. Ghansah Ph.D., S. May and K.HT Paraiso MS.
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SHIP is found associated with Ly49 receptors where it may control the level of
PI(3,4,5)P3 generated by PI3K and negatively regulate Akt phosphorylation

Analysis of potential SHIP interaction with different Ly49 receptors,
revealed that SHIP is associated with Ly49A and Ly49C under physiological
conditions (Figure 29A), but not with Ly49G2, Ly49F, or Ly49I (Figure 29B). As
further confirmation that the protein co-precipitating with Ly49A and Ly49C is
SHIP, we analyzed NK lysates from SHIP+/+ and SHIP-/- mice (Figure 29C).

This analysis detected co-precipitation of SHIP with Ly49A and Ly49C only
in the SHIP+/+ NK lysates, confirming the specificity of the Western Blot.
Because SHIP limits the in vivo survival of myeloid cells by opposing the
PI3K/Akt pathway,2,3 we examined whether Akt is activated in SHIP-/- NK cells in
vivo based on its phosphorylation at Thr308.321,322

We found that both Akt

phosphorylation and total Akt protein levels were significantly increased in SHIP-/NK cells relative to those in SHIP+/+ NK cells (Figure 29D). The increase in total
Akt levels is surprising; however, primary B cell activation leads to increased Btk
levels in a PI3K-dependent manner.323 This additional level of regulation may
further amplify signals from PH domain-containing kinases, such as Akt or Btk,
which are recruited to PI(3,4,5)P3.

Taken together, these findings suggest the

interplay of SHIP and PI3K may influence the relative survival of NK subsets
expressing Ly49 receptors capable of recruiting these enzymes. Interestingly,
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PI3K is recruited to human KIR and can activate Akt in human NK cells.324 Thus,
despite their evolutionary divergence in how they bind MHC class I molecules,
murine Ly49 receptors and human KIR may recruit SHIP to limit the in vivo
survival of NK subsets, just as both receptors recruit Shp-1 to limit NK effector
functions.310,325

Figure 29. SHIP is recruited to NK inhibitory receptors in vivo to oppose activation of
Akt.

(A) Western blot detection of SHIP in Ly49A and Ly49C immunoprecipitates.

Immunoprecipitation with a murine IgG2a antibody (IgG2a) was analyzed as a negative
control and SHIP was immunoprecipitated as a positive control (SHIP). (B) Western
blotting for SHIP in other Ly49 immunoprecipitates (Ly49G2, Ly49F, and Ly49I). (C)
Western blot analysis of SHIP in Ly49A and Ly49C immunoprecipitates prepared from
lysates of SHIP+/+ (+/+) and SHIP−/− (−/−) NK cells. (D) Western blot analysis of Akt
phosphorylation at Thr308 and total Akt protein in SHIP+/+ and SHIP−/− NK cell lysates. To
control for equal loading the blot was re-probed with antibodies specific for β-actin,
GAPDH, and α-tubulin. Collaboration with T. Ghansah Ph.D., and K.H.T Paraiso MS.
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DAP12 is Expressed by SHIP-/- BM Cells and NK Cells

According to our data, the disruption in NK cell receptor repertoire in
SHIP-/- mice appears to result from a bias towards selection for Ly49A and C
receptors, due to their increased survival. Consequently, the level of Ly49D+ NK
cells in SHIP-/- mice is decreased was compared to WT mice. However, we
wanted to determine if the decrease in Ly49D+ NK cells representation did not
arise from a lack of DAP12 expression. It has been shown that Ly49D and other
activation receptors require the presence of DAP12 to migrate to the cell
surface.326 Thus, we considered the possibility that Ly49D was not found on the
surface of SHIP-/- NK cells due to the absence of its adaptor molecule DAP12.
However, using reverse-transcription PCR (RT-PCR), we observed that DAP12
is expressed in SHIP-/- BM (Figure 30A) and SHIP-/- NK cells as well as WT
(Figure 30B). Another molecule known to be involved in transduction of extracellular signaling by NK cell receptors is DAP10.

Like for DAP12, we also

observe that SHIP-/- and WT BM cells express the DAP10 adaptor molecule
(Figure 31). Since we can detect DAP12 by RT-PCR it suggests that Ly49D
receptors should reach the SHIP-/- NK cell if they were to be expressed.
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Figure 30. DAP12 is expressed in SHIP-/- and WT BM cells and NK cells. RNA from (A)
BM and (B) NK cells was isolated and RT-PCR was performed to assess the presence
of DAP12.

Figure 31. DAP10 is expressed in SHIP-/- and WT BM cells. RNA from BM cells was
isolated and RT-PCR was performed to assess the presence of DAP10.

113

SHIP but not Shp-1 is Found Associated with Ly49A under Physiological
Conditions

Signal transduction studies on NK cells have relied for a long time on the
study of lymphokine-activated killer (LAK) cells. These cells are splenocytes that
are grown for approximately 7 days in a media containing a combination of
cytokines that promote NK cells proliferation. After this 7-day culture, the cells
are collected and activation experiments are performed. Several group observed
that when LAK cells were treated with pervanadate, Shp-1 was recruited to the
tyrosine-phosphorylated ITIM sequence of Ly49A molecule.308

Once to the

membrane, Shp-1 can dephosphorylate molecules such as Syk, PLCγ-1/2,
ZAP70, and Shc,42,310 leading to their deactivation, preventing NK cell from killing
target cells. Instead of culturing the cells for 7 days, we studied the biology of NK
cells right after isolation, which would be closer to physiological condition. In this
experiment we observe that SHIP does co-immunoprecipitate with Ly49A, while
Shp-1 does not (Figure 32A, B). This confirms that the roles of SHIP and Shp-1
in NK cell biology are very different (Figure 33). While Shp-1 appears to be
important for the control of activation signaling after Ly49 engagement, SHIP
seems to play a role in NK cell homeostasis and maintenance of receptor
repertoire.
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Figure 32. SHIP but not Shp-1 is recruited to NK inhibitory receptor Ly49A in vivo. (A)
Western blot detection of SHIP in Ly49A IP, Ly49G, a murine IgG2a antibody (IgG2a) IP
used as a negative control. WCL from 70Z/3 and NK cells (same lysate than the one
used for IP) were used as positive control. (B) Western blot detection of Shp-1 in Ly49A
IP, Ly49G, a murine IgG2a antibody (IgG2a) IP used as a negative control. WCL from
A431 and NK cells (same lysate than the one used for IP) were used as positive control.
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Figure 33. Signaling pathways downstream of Ly49A and C that can be influenced by
SHIP in NK cells. As shown on this schematic representation of NK cells signaling
pathways. SHIP, by being recruited to Ly49A and C can negatively control the survival
and proliferation of NK cells in response to encounter with self H2b encounter. Once NK
cell activation receptors are also engaged, Shp-1 will be recruited to the membrane to
Ly49 receptors, where it will dephosphorylate kinases that, when activated, trigger an
attack on target cells.
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Discussion
Our study shows that F4 SHIP-/- mice have an increased number of
peripheral NK cells, and that their receptor repertoire is disrupted. This suggests
that NK cells might undergo some sort of selection process once they acquire
their Ly49 receptors during development.

The interaction of these NK cell

inhibitory receptors with self MHC ligands may elicit signals that promote the
survival or proliferation of these cells in vivo.327 Thus, NK cells could be selected
for their ability to be engaged by host MHC molecule (Table 3), which would
ensure that the NK cells in an organism express the proper inhibitory receptors to
prevent unwanted attack on self.

SHIP, once recruited to the membrane by

some of these Ly49 receptors could negatively regulate their survival and
proliferation by controlling signaling pathways downstream of PI3K.

Alternatively, SHIP could be recruited to the membrane by Ly49 receptors
to participate in the control of NK cell activation, as it has been shown to
negatively control calcium influx in mast cells.99,241 In addition, PI3K276,277 and
PLCy molecules278-280 have been shown to play a role in NK cell activation.
Since SHIP has the potential to dephosphorylate PI(3,4,5)P3, it could downregulate
these signaling pathways.10,56-59,62,63

However, this scenario seems highly

unlikely since SHIP-/- NK cells are unable to kill allogeneic transplant43 and are
not as efficient as WT NK cells in lysing target cell in an in vitro assay.43
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On the other hand, SHIP is known to control signaling pathways
downstream of cytokine receptors that can lead to activation of transcription
factors, which could potentially impact Ly49 expression.328,329 Up to this date the
transcription regulation of NK cells receptors, including Ly49 receptors, appears
to be highly stochastic with each receptor gene containing up to 3 separate
promoters.330 Thus, more studies are necessary to understand the mechanism
for Ly49 variegated gene expression. Interestingly, NFκB has been implicated in
the regulation of the probabilistic switch regulating Ly49 receptors expression.331
Knowing that SHIP can impact NFκB activation,332 SHIP-deficiency could perturb
Ly49 transcription regulation. Interestingly, PLCγ2-/- mice also have a disrupted
Ly49 receptor repertoire.279 This suggests that pathways downstream of PI3K
are important for the establishment of a proper Ly49 receptor repertoire.

Materials and Methods

FACS Analysis of the NK Cell Compartment and their Receptors

To analyze the peripheral NK cell compartment spleens were collected
from mice at various ages. A single cell suspension was prepared by crushing of
the spleen with a syringe plunger, and NH4Cl lysis (Red blood cell lysis buffer,
eBioscience) of erythrocytes.

The cells were then stained with an antibody

against the Fc receptor to prevent unspecific binding. All antibodies were from
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BD Biosciences, except where mentioned.

For the NK cell compartment

assessment, splenocytes were stained with fluorescently conjugated antibody
against the NK-associated markers 2B4-PE, NK1.1-FITC and CD3-APC. The
cells were then incubated into a solution of 7AAD (5 μl per 1 million cells) for
dead cell exclusion. Data acquired on FACS Calibur with CellQuest software,
and analyzed with FlowJo. For the receptor repertoire analysis, isolated and Fc
blocked splenocytes were stained with 2B4, NK1.1 and anti-Ly49A (A1), -Ly49C/I
(5E6), -Ly49D (4E5), -Ly49G2 (4D11) or -CD94 (eBioscience). To distinguish
Ly49C staining from Ly49I, cells were stained with NK1.1, Ly49C/I and Ly49I
(YLI90). All biotin conjugates were revealed by Streptavidin-APC (eBioscience).
Cells were then exposed to 7AAD for dead cell exclusion and data was acquired
on FACS Calibur with CellQuest software, and analyzed with FlowJo.

Protein Lysis Buffers

Radioimmunoprecipitation (RIPA) buffer.

The modified RIPA buffer

protocol was obtained from the Upstate catalog. To prepare 100 ml of RIPA
buffer, add 790 mg of Tris base (Fisher) to 75 ml of distilled water, add 900 mg of
NaCl (Fisher), adjust the pH to 7.4 with HCl, then add 10 ml of 10% NP-40, 2.5
ml of 10% Na-Deoxycholate and 1 ml of 100 mM EDTA, adjust the final volume
to 100 ml with distilled water and store at 4oC until use. Right before using the
buffer add protease and phosphates inhibitors to it.

119

A cocktail of protease

inhibitors from Sigma-Aldrich was used at a concentration of 0.1%, or 10 μl of
protease inhibitor cocktail in 1 ml of RIPA. For phosphates inhibitor, we use
pervanadate (NaVO3) to a final concentration of 1mM, thus add 10 μl of 100mM
NaVO3 to 1 ml of RIPA buffer.

Digitonin cell lysis buffer. First, weigh 0.5 g digitonin (CalBiochem, EMD
Biosciences, Inc., San Diego, CA, USA) into a 50 ml tube add 25 ml ddH2O and
boil for about 2 h. Allow to cool on the bench and if a precipitate forms, boil
again for longer period of time, until no more precipitates are found after cooling.
Then, add the following reagents: 0.6 ml of 10 % Triton X-100, 1.5 ml of 5 M
sodium chloride (NaCl), 10 ml of 100 mM Triethanolamine, pH 7.8, 125 μl of 1 M
calcium chloride (CaCl2), 50 μl of 1 M magnesium sulfate (MgSO4), 25 μl of 20 %
Sodium Azide and top with ddH2O to 50 ml. As for the RIPA buffer, the protease
and phosphatases inhibitors were added right before use. Immunoprecipitation
was carried as mentioned in the next section. After immunoprecipitation, the
precipitated beads were washed 4 times with a solution that prevents (or
diminishes) the detection of unspecific interaction.

This washing buffer

surnamed FROPS buffer contains 30 ml of 5 M NaCl, 5 ml of 1M CHAPS, 50 ml
of 1 M Tris pH8 brought up to 1 liter using deionized distilled water.
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Biochemical Analysis of SHIP and Akt

NK-enriched C57BL6/J splenocytes were prepared by depletion of B cells
and macrophages by adherence to nylon wool followed by T cell depletion using
anti-CD3 plus complement. NK cells were then lysed in modified RIPA buffer or
digitonin buffer.

Prior to immunoprecipitation the NK cell lysates were pre-

cleared twice by incubation with 0.25 μg of an murine or rat IgG2a antibody (BD
Biosciences) and 50 μl of Protein A-Agarose or Protein G-Sepharose beads
(Upstate, Charlottesville, VA, USA). The beads were pelleted at 15,000 RPM for
15 minutes at 4°C. The pre-cleared supernatants were immunoprecipitated with 2
μg of anti-Ly49A (A1), -Ly49C/I (5E6), -Ly49F (HBF-719), -Ly49G2 (4D11), Ly49I (YLI-90) or IgG2a (BD Biosciences). To pre-clear the lysate and as a
negative control for immunoprecipitation, mouse IgG2a was used for Ly49A and
Ly49C/I immune precipitates, rat IgG2a was used for Ly49G2 immune
precipitates, and mouse IgG1 was used to for Ly49F and Ly49I immune
precipitates. Immune complexes were precipitated by addition of 50 μl of Protein
A-Agarose (Ly49A, Ly49C/I) or Protein G-Sepharose (Ly49F, Ly49G2, Ly49I)
beads.

The

immunoprecipitates

were

resolved

on

a

4-12%

Tris-Bis

polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham
Pharmacia, Piscataway, NJ). The filters were then probed with a 1:1000 dilution
of anti-SHIP (P2C6, a kind gift of Larry Rohrschneider) and a horseradish
peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody (Amersham
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Pharmacia) at a 1:80,000 dilution. The presence of SHIP was revealed using the
SuperSignal West Femto reagent (Pierce Biotechnology Inc., Rockford, IL, USA).
The results of the Ly49 immunoprecipitations in Figure 29 and 32 are
representative of three independent analyses of NK-enriched splenocytes. For
analysis of Akt activation lysates of purified NK cells from the spleens of SHIP-/and SHIP+/+ were prepared as above.

Equal quantities of protein from cell

lysates prepared from SHIP+/+ and SHIP-/- NK cells were resolved on a 4-12%
Tris-Bis polyacrylamide gel (Novex/Invitrogen, Carlsbad, CA, USA), transferred
to a nitrocellulose membrane (Amersham Pharmacia) and the filters probed with
an anti-Phospho-Akt(Thr308) antibody (Cell Signaling Technology, Danvers, MA,
USA) at a 1:1000 dilution.

The presence of Akt was detected by a HRP-

conjugated donkey anti-rabbit IgG secondary antibody (Amersham Pharmacia) at
a 1:2000 dilution and revealed using ECL substrate (Amersham Pharmacia). The
blot was then stripped and reprobed in a similar manner using anti-β-actin (Cell
Signaling Technology), anti-GAPDH (Research & Diagnostics Antibodies,
Benicia, CA) and anti-α-tubulin (Oncogene Research, Cambridge, MA) as
internal controls for protein loading. The detection of increased Akt levels and its
activation is representative of three separate analyses of NK cell lysates from
SHIP-/- and SHIP+/+ mice.
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RT-PCR for DAP10 and DAP12

Cells were isolated as mentioned above. For the NK cells RNA extraction,
splenocytes were first treated with Fc block (CD16/CD32) for 15 minutes to
prevent unspecific binding. The cells were then exposed to NK1.1-FITC (NK1.1)
and CD3ε-PE (145-2C11). The FACS Vantage with the DiVa software was then
used to sort CD3-NK1.1+ or CD3-NK1.1++ cells in the presence of 7AAD to
exclude to dead cells.

All antibodies were from BD Biosciences. RNA was

isolated following the protocol for the RNAqueous-4PCR kit (Ambion, Austin, TX,
USA). RT-PCR was performed using MultiScribe reverse transcriptase (Applied
Biosystems, Foster City, CA, USA) protocol. Briefly, 5xRT-PCR buffer (4 μl), 25
mM MgCl2 (2 μl) 10 mM dNTP (2 μl), RNase inhibitor (0.5 μl), 100 mM DTT (2 μl)
and random hexamers (0.5 μl), were mixed with RNase free water (up to 20 μl)
and RNA isolated from tested samples (equivalent of 10 000 cells). The enzyme,
0.3 μl of MultiScribe RTase was then added to the reaction right before starting
the reverse transcription on a Px2 thermal cycler PCR machine (Thermo Electron
Corporation, Waltham, MA) using the following program; 10 minutes at 25oC and
12 minutes at 42oC. The RT-PCR products were then placed at 4oC for 1-2
hours. 10 μl of the RT-PCR reaction was then used for a PCR reaction using the
primers for specific genes. Briefly, cDNA (10 μl), RNase free water (25 μl), 5x
AmpliTaq buffer, (8 μl) 25 mM MgCl2 (2.5 μl), 10nM dNTP (3 μl), 20 μM DAP12
forward and reverse primers (.5 μl each) and 0.5 μl of AmpliTaq (Applied
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Biosystems) were mixed then PCR reaction was performed. PCR reaction was
done on Px2 thermal cycler PCR machine using the following program; 10
minute polymerase activation at 95oC, 43 cycles of 25 second at 94oC and 1
minute at 60oC, and then a final incubation at 72oC for 7 minutes. The expected
PCR product for DAP12 was 120 nucleotides and the band on the 1.2% agarose
gel appears to be 120. When the PCR was performed for DAP10, DAP 10
forward and reverse primers were used for the PCR reaction, otherwise every
thing else was as mentioned earlier, a 126 base pairs sequence was expected,
as seen on the 1.2% agarose gel. Primers used for DAP10: Forward: 5’-caa gtc
aga cat cgg cag gtt c-3’ and Reverse; 5’-gca tac ata caa aca cca ccc cta-3’.
Primer used for DAP12 Forward: 5’- cct tcc tgt cct cct gac tgt g and Reverse 5’tca ccc aga aca atc cca gc-3’.

Western Blot for Shp-1

Lysis and immunoprecipitation was carried as mentioned above.

The

same immunoprecipitate was then loaded on two different gels, one for Western
blot with SHIP and the other one with Shp-1. The Western Blot and probing for
SHIP was performed as mentioned above. The membrane to be probed for Shp1 was then blocked in 5% non fat milk (NFM) in TBS (TBS-5%NFM) for 20
minutes at RT with constant agitation.

The membrane was then incubated

overnight at 4oC in TBS-5%NFM containing 1 μg/ml of anti Shp-1 antibody
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(Upstate). The morning after the membrane was washed twice in distilled water
and incubated for 1.5 hour at RT in TBS-5%NFM containing HRP conjugated
anti-rabbit antibody (Cell Signaling Technology) at a concentration of 1:80,000.
The membrane was then washed twice in distilled water, and once in TBS-0.05%
Tween 20 for 5 minutes. The membrane was washed another 5 x in distilled
water and revealed using the SuperSignal West Femto for 5 minutes (Pierce
Biotechnology Inc.).
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Section IV: Murine ES Cells and s-SHIP
Introduction to ES Cells

Murine ES (mES) cells are pluripotent cell lines derived from the culture of
preimplantation embryos or epiblasts.333-335 These cells have the potential to
differentiate into any cells of an organism. ES cells, contrarily to cells from 2cells-stage embryo, can not form the trophoblast, and therefore, should be
referred to as pluripotent and not totipotent.336 ES cells can be derived and
grown for several passages, without any intervention or immortalization agent.
Throughout this process ES cells do not undergo senescence and retain their
diploid karyotype. They can multiply in the absence of serum, if in the presence
of feeder layer, and are not subject to contact inhibition or anchorage
dependence.337 Once ES cells are injected into a developing blastocyst, they
have the potential to integrate that blastocyst and change parts of its genetic
background.

Successful integration of ES cells into blastocyst results in the

colonization of germ cells.337 These mice are then considered chimeras and can
produce functional gametes containing the genetic background of the injected ES
cells. Thus, ES cells have a tremendous potential to be used as a vehicle for
introducing genetic modification in mice and many other organisms.
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It is

important to note that injection of ES cells in adult mice has been associated with
the formation of teratocarcinoma.334

The maintenance of ES cells in vitro is

paramount for the development of genetic manipulation strategies, therefore
understanding the process of self-renewal versus differentiation is very important.

The first mES cell lines were derived by growing these cells on fibroblast
feeder layers. However, the presence of these feeder cells made the study of
mES cell signaling very difficult. Then, Smith and Hoopers found that mES cells
could be grown, undifferentiated, in the presence of FBS and LIF.338-340
Furthermore, it was established recently that signaling by bone morphogenetic
proteins (BMP) works together with LIF to maintain the pluripotency of mES
cells.341,342

ES Cells Signaling Pathways

LIF and ES cells. In mES cells, LIF, coming from the feeder layer or given
in the culture media as a recombinant protein, appears to be essential for the
maintenance of ES cell pluripotency.338-340 LIF is a factor that belongs to the IL-6
cytokine family, which also includes IL-11, ciliary neutropic factor, oncostatin M
and cadiotrophin-1.343 LIF engages the heterodimerization of receptor complex
composed of LIFr and gp130, gp130 being a common receptor subunit of the IL6 cytokine family receptor.344,345 The heterodimerization of this complex leads to
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activation of janus associated kinases (JAKs) that phosphorylate the receptor
chain (Figure 34).

Figure 34. LIFR/gp130 receptor complex signal transduction pathways and how s-SHIP
may impact them in pluripotent stem cells. Based on research from several groups, it
was found that the LIFR/gp130 receptor complex can impact ES cell self-renewal and
differentiation.337,346-348

Although s-SHIP does not become phosphorylated after LIF

stimulation, s-SHIP is constitutively present at the membrane and thus can impact the
signaling pathways downstream of ES cell receptors. As illustrated above, LIFR/gp130
has the potential to trigger either differentiation or self-renewal depending on which
downstream signaling components are activated.
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The phosphorylated tyrosine on LIFr/gp130 complex can then serve as
anchor site for SH2 containing domains. Some of the molecules recruited to the
activated LIF/gp130 receptor complex consist of signal transducer and activator
of transcription 3 (STAT3),349 PI3K,350 Erk,337,351 and Shp-2.352,353 These proteins
can then be activated by surrounding kinases354-356 and exert their effect.
Interestingly, the activation and formation of protein complexes between these
different proteins create a very fragile balance between self-renewal vs.
differentiation during proliferation signaling.337

STAT3 stimulates ES cell self-renewal. In mES cells, LIF predominantly
activates STAT3,349 and it appears to be essential for self-renewal (Figure 34).357
Consequently, down regulation of STAT3 through expression of a dominant
negative protein causes ES cell to differentiate. Studies using a chimeric STAT3
molecule directly activated by estradiol showed that STAT3 is not only necessary
but might even be sufficient to block differentiation of mES cells.358

ERKs antagonize ES cell self-renewal. While recruitment of STAT3 to the
activated LIFr/gp130 leads to self-renewal of ES cell, recruitment of Shp-2 and
Grb2 will lead to stimulation of the Erk1/2 (p42/44) and differentiation of ES cells
(Figure 34).346

Attenuation of ERK and Shp-2 signaling (by pharmacological

inhibition of MAPK or by overexpression of Erk phosphatase) result in an
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increase in self-renewal by reduction of differentiation.347 However, inhibition of
ERK does not replace the Stat3 requirement but enhances its action (direct or
indirectly) in the promotion of ES cells self-renewal.347 The balance between
these two major signaling pathways is important for ES cells maintenance. Once
phosphorylated, LIFr/gp130 receptor can recruit SH2 domain containing protein
such as Shp-2.352,353,356

Grb2 will then bind Shp-2, which will result in the

recruitment of SOS to the membrane. Once SOS is at the membrane, it can then
activate RAS/RAF/MAPK/Erk and downstream transcriptional factors such as,
Myc, Ets, Elk, and SRF.359

Furthermore, Shp-2 also associates with Gab1, which can recruit PI3K.360
The resulting phospholipids, PI(3,4,5)P3, can then provide a binding site for the PH
domain of Gab1, stabilizing the association of Shp-2/Gab1/Grb2/Sos complex at
the membrane and facilitating coupling to RAS signaling pathway (Figure 34).361
However, the production of PI(3,4,5)P3 can also promote the recruitment of
molecules that can increase survival or proliferation of the cells, such as Akt,
which has been shown to stimulate ES cell self-renewal.362

Since SHIP, has been implicated in the control of several of these
signaling pathways, s-SHIP might also impact some of these pathways. Even if
s-SHIP lacks the SH2 domain and does not appear to bind Shc, it does bind
Grb2 and might be involved in the control of protein complex formation of
Grb2/Shp-2/Gab1/Sos, which leads to differentiation stimulation.49 Furthermore,
130

s-SHIP has been shown to be constitutively located at the membrane49 where it
could hydrolyze the 5’ phosphate of PI(3,4,5)P3363 and dampen signaling
downstream of PI3K, such as Akt or Gab1 activation.

PI3K signaling in ES cells.

Inhibition of PI3K using drug inhibitor or

dominant negative delta85, led to a decrease in Akt, GSK3alpha/beta, and S6
proteins activity and an increase in Erk phosphorylation, resulting in a reduction
of self-renewal.350 One of the lipid phosphatases responsible for degradation of
PI(3,4)P2 and PI(3,4,5)P3 levels, is PTEN. In fact, PTEN-/- ES cells have enhanced
viability and rate of cell proliferation, correlated with increased level of PI(3,4,5)P3
and phosphorylation of Akt, and inactivation of Bad (a pro-apoptotic protein).364
The absence of PTEN results in an increased cell division rate, which is much
more important in ES cells than in fibroblasts, suggesting that PI3K signaling is
more important in ES cells than fibroblast.337 Even though PTEN appears to be
primarily responsible for PI(3,4,5)P3 degradation and down modulation of PI3K
effector signaling pathways in ES cells, s-SHIP could also have a role in this
process.

131

s-SHIP

s-SHIP is a predicted 104/97kDa protein that is expressed by ES cells and
HSC but not normal lineage differentiated cells.43 s-SHIP can be amplified by
RT-PCR using primers that span the carboxyl terminal end of SHIP but not by
primers that bind the amino terminal region.49 This is explained by the fact that sSHIP sequence lacks the SH2 domain found in full-length SHIP.49

Studies revealed that s-SHIP is the murine homologue of human SIP-110.
Similar to s-SHIP, SIP-110 is a 109kDa SHIP isoform protein that lacks the SH2
domain.4 We observed that the first exon of SIP-110 and s-SHIP share 82%
homology. Furthermore, s-SHIP has a 44 nucleotides sequence in its amino
terminus that is not present in SHIP cDNA, this region was named stem-SHIP
region (SSR).49

In SIP-110, a similar 42 nucleotides SSR-like sequence is

observed.49 In our paper, it was proposed that s-SHIP, like SIP-110, resulted
from the utilization of a different transcriptional start site than full-length SHIP,
this start site would be embedded within the intron 5/6 of SHIP.49 It was recently
shown that the intron 5/6 contains a promoter region that can drive the
expression of a green fluorescent protein (GFP) construct in knock-in mice
stem/progenitor cells, including regions where breast mammary stem cells
reside.55 Interestingly, others observed that SHIP-deficient ES cells express sSHIP at higher levels and for a longer period of time when primed to differentiate
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than WT ES cells.365 Since s-SHIP appears to be selectively expressed in ES
cells and HSC, but not in lineage differentiated cells,49 we were interested in
studying the signaling pathways in which this protein might be involved.

s-SHIP and ES Cell

ES cells maintain pluripotency through stimulation of several signaling
pathways.366 In vitro culture of murine ES (mES) cells requires the presence of
fibroblast feeder layer cells and/or LIF when grown on gelatin-coated
paltes.339,340,367 LIF engages the heterodimeric receptor complex composed of
gp130 and LIF receptor (LIFR) and supports the culture of mES cells in the
absence of a feeder layer.368 Several signal transduction molecules have been
shown to play a role in the survival, self-renewal, and/or proliferation of mES cells
via the LIFR/gp130 axis, such as Stat3,349 PI3K,350 Erk,337 and Shp-2.347
Interestingly, the activation and formation of protein complexes among these
different proteins establishes the delicate balance between self-renewal and
differentiation pathways in pluripotent stem cells.337

In different cell models, several signaling pathways important for
proliferation and survival downstream of PI3K can be downregulated by inositol
phosphatases such as PTEN,364,369 SHIP1,

3

and SHIP2.77,370,371 In particular,

SHIP1 can be recruited to the membrane, where it can hydrolyze the 5’phosphate of PI(3,4,5)P3 or I(1,3,4,5)P4.2
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In this manner, these inositol

phosphatases oppose the activity of PI3K by preventing the recruitment of
pleckstrin homology (PH) containing kinases such as Akt and Btk. Previously,
we found that ES cells and, to a lesser extent, HSC, express an isoform of
SHIP1, s-SHIP. This isoform is not expressed in normal mature hematopoietic
cells, making this molecule an excellent candidate as a key factor in the
regulation of stem cell signal transduction pathways.

In previous studies, we showed that s-SHIP interacts with Grb2 and does
not with Shc.49 In this present study, we show that s-SHIP is expressed by mES
cells, but not by the mouse embryonic fibroblasts (MEF) that support their
undifferentiated growth. MEF cells, however, do express the full-length SHIP
isoform. In addition, we demonstrate that murine BM cells lacking the promoter
and first exon of the full-length SHIP gene still express s-SHIP.

This result

confirms that expression of s-SHIP is not dependent on the upstream promoter
active in differentiated cells. Knowing that the major growth factor for ES cell
self-renewal and proliferation is LIF (Figure 34), we used this growth factor to
stimulate ES cells to determine if it can stimulate s-SHIP phosphorylation. We
observed that s-SHIP does not become tyrosine phosphorylated following
stimulation of ES cells with LIF. Finally, we show that s-SHIP associates with
gp130 in vivo in ES cells. These findings implicate s-SHIP in signaling pathways
that control the self-renewal and differentiation of pluripotent stem cells.
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Aims:
1) Define if s-SHIP is expressed in MEF and SHIP-/- BM cells.
2) Study what pathway s-SHIP might impact

Results
MEF Cells Express Full-Length SHIP, but Only ES Cells Express the s-SHIP
Isoforms
In our previous study, we analyzed SHIP and s-SHIP protein expression in
ES cells after transfer from MEF feeder layer to gelatin-coated dishes.49
Occasionally, we would find by Western blot analysis that some ES cell cultures
grown on gelatin would express some levels of the full length SHIP isoform.49
We attributed this to residual contamination of the ES cell culture with MEF. To
resolve this issue, we established a culture of MEF cells alone, ES cells on MEF
cells, and ES cells on gelatin. Our suspicion that MEF cells express SHIP was
confirmed as we found that MEF express the 145/135kDa full-length SHIP
doublet, but not the s-SHIP 104/97kDa doublet (Figure 35). In a culture of ES
cells growing on MEF cells, SHIP and s-SHIP are present (Figure 35). The
protein lysate used in the third lane was produced using ES cells propagated on
gelatin-coated dishes in the presence of LIF for several passages. This was
done to reduce as much as possible the contribution of MEF cells to the analysis.
The protein lysate of these ES cells, grown on gelatin, revealed that these cells
express only the s-SHIP doublet (Figure 35).
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Figure 35. MEF cells express full-length SHIP, while ES cells express only s-SHIP.
Protein lysates from MEF cells grown alone, ES cells grown on MEF cells, and ES cells
grown on gelatin were analyzed for the expression of the different SHIP isoforms.
Western blot was performed using the Novex/Invitrogen system. SHIP and s-SHIP were
revealed using P2C6 anti-SHIP antibody and anti-mouse-HRP. Chemoluminescence
was detected using SuperSignal Femto (Pierce Biotechnology Inc.).
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SHIP-/- Murine BM Cells Express s-SHIP

In our laboratory, we established a SHIP-/- mouse model by deletion of the
promoter and exon 1 of the SHIP gene using the Cre-loxP technology.43 This
deletion led to the ablation of SHIP production.43

As previously published,

bioinformatic analysis predicted that the s-SHIP and SIP-110 promoter is in the
intron 5/6 of the SHIP gene.49 Therefore, we theorized that SHIP-/- HSC might
retain s-SHIP expression, since the internal promoter in intron 5/6 is intact in this
SHIP-/- model. As we anticipated, s-SHIP mRNA is detected in SHIP-/- BM cells
by nested RT-PCR (Figure 36).

This result is consistent with a study by

Rohrschneider et al (2005), in which the s-SHIP promoter region in SHIP intron
5/6 promotes transcription of a reporter gene in stem and or early progenitor cells
of a transgenic mouse model.55

Figure 36. Nested RT-PCR detection of s-SHIP expression in SHIP-/- BM. Nested RTPCR was performed, using sets of primers that span the SSR (1-44) region, unique to sSHIP.

Initial round of amplification (43 cycles) with primers F1-25 and R459-478,

secondary round of amplification (43 cycles) with primers F21-41 and R439-463.
Amplified DNA was then resolved on a 2% agarose gel. Legend: 1) Hela cells, 2) WT
WBM C57BL6, 3) SHIP-/- WBM C57BL6, 4)WT WBM BalbC, 5) no RNA, 6) No RTase
with RNA from WT C57BL6 BM cells, 7) No polymerase with RNA from WT C57BL6 BM
cells).
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s-SHIP Does Not Become Phosphorylated Following LIF Stimulation

The SHIP isoform expressed in mature hematopoietic cells is tyrosine
phosphorylated

upon

stimulation

by

growth

factor,1,21,372

immune

complexes,5,34,372,373 or BCR engagement.33,372,374 Phosphorylated SHIP is found
associated with the adapter protein Shc, which facilitates its recruitment to the
plasma membrane33 where it can then act on phosphatidylinositol substrates.
However, we found that s-SHIP is not tyrosine phosphorylated in either ES cells
grown in LIF at steady state or ES cells deprived of LIF for 5 hours and
subsequently stimulated with 2× LIF (Figure 37). It was also observed that sSHIP does not associate with Shc either at steady-state or after LIF stimulation.49
Instead, s-SHIP co-immunoprecipitates with Grb2.49 Furthermore, it has been
observed that SHIP or SIP110 do not need to be phosphorylated to exert their
catalytic effect.54 Thus, it is highly probable that s-SHIP, can control PI(3,4,5)P3
accumulation in ES cells, despite not being phosphorylated.
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Figure 37.

ES cells express the s-SHIP protein isoform that does not become

phosphorylated

following

growth

factor

stimulation.

Immunoprecipitation

and

immunoblot detection of s-SHIP in ES cell lysates. Lysate from ES-TL1 cells cultured in
LIF was immunoprecipitated with the P2C6 anti-SHIP monoclonal antibody, separated
on gels, transferred to membranes, and probed with P2C6, revealing 104-kd and 97-kd
proteins (lane 5). No tyrosine phosphorylation of these proteins was detected when they
were probed with the 4G10 anti-phosphotyrosine antibody. For comparison, lysates from
293T cells transfected with SHIP cDNA (lane 1) and s-SHIP cDNA (lane 2) were
included in the blots. To further assess the tyrosine phosphorylation status of s-SHIP,
timed LIF stimulation studies were performed. ES-TL1 cells incubated for 5 hours
without LIF were stimulated with 2000 U/ml LIF for 0, 2, 5, or 10 minutes and were
rapidly lysed. Equal amounts of total protein were immunoprecipitated with the P2C6
antibody and probed separately with the P2C6 and 4G10 antibodies (lanes 6-9). No
tyrosine phosphorylation of s-SHIP was detected at any time point with the 4G10
antibody. For comparison, A20 B-lymphoid cells were stimulated with anti-IgG antibody
for 0 or 5 minutes, lysed, immunoprecipitated with P2C6, and probed with P2C6 and
4G10 (lanes 3,4), showing prominent tyrosine phosphorylation of SHIP at 5 minutes.
Molecular mass standards are indicated on the right. Collaboration with J. Ninos MD.
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s-SHIP Associates with gp130 In Vivo

Grb2 has been shown to be present in protein complexes formed after
gp130 engagement. Since Grb2 can associate with s-SHIP, we assessed the
potential of s-SHIP to associate with gp130 in ES cells. As demonstrated in
Figure 38A and B, s-SHIP is present in gp130 immunoprecipitates from protein
lysates of ES cells at steady state. This result strongly suggests that s-SHIP is
present in protein complexes that interact with gp130 in ES cells. Inhibition of the
s-SHIP/gp130 association by preincubation of gp130 antibody with specific
blocking peptides establishes the specificity of the interaction (Figure 38B). This
result provides a direct link between s-SHIP and an important signaling
component of the pathway influencing ES cell self-renewal.
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Figure 38. s-SHIP is associated with gp130 in ES cells. A) Lysates of ES cells grown
on gelatin were immunoprecipitated with gp130 antibody, s-SHIP antibody (positive
control) and rabbit antibody (negative control). (B) Lysates of ES cells grown on gelatin.
Whole

cell

lysate

(positive

control),

immunoprecipitate

with

gp130

antibody,

immunoprecipitation with gp130 antibody previously blocked with specific peptides,
immunoprecipitate with Grb2 antibody, immunoprecipitation with Grb2 antibody
previously blocked with specific peptides, and immunoprecipitate with rabbit antibody
(negative control).

141

Discussion

In this study, we show that s-SHIP co-immunoprecipitates with gp130.
This further suggests that s-SHIP can be found intimately associated with protein
complexes that impact self-renewal and proliferation pathways of mES cells. sSHIP may interact with gp130 directly, or indirectly, through an intermediate such
as Grb2. The exact role that s-SHIP plays in ES cell biology remains to be
defined.

As shown previously, s-SHIP is found constitutively at the plasma

membrane in ES cells.49 Furthermore, it has been shown previously that SIP110
phosphorylation is not required for enzymatic activity.

Thus, s-SHIP could

downregulate basal activation of Akt in these cells through degradation of
PI(3,4,5)P3.363 In this context, the role of s-SHIP would be to limit cell survival
(Figure 34).

Interestingly, PI3K inhibition leads to a decrease in PI(3,4,5)P3,

resulting in Erk activation and a reduction in self-renewal. Therefore, s-SHIP
may negatively control ES cell self-renewal.

Since PTEN appears to be

necessary for the control of pathway downstream of PI3K in ES cells,364 s-SHIP
and PTEN might have a redundant role in controlling this pathway.

Alternatively, s-SHIP would associate with Grb2 to prevent the formation
of the protein complex composed of Shp-2, Grb2, and SOS, and thereby limit the
activation of MAPK and the downstream differentiation of ES cells (Figure 34). In
previous studies, it was shown that s-SHIP expression declines as the stem cell
differentiates into specific lineages.49,365 Furthermore, SHIP-/- ES cells express
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higher levels of s-SHIP and for a longer period of than WT ES cells.365 Thus, ES
cells might express the s-SHIP isoform to inhibit differentiation stimuli, since it
binds Grb2 constitutively, potentially preventing the association of Shp2/Grb2/SOS protein complexes (Figure 34).

Interestingly, the SHIPΔIP/ΔIP mice, produced by targeting the inositol
phosphatase domain, are viable,97 despite the likelihood that they do not express
an enzymatically active form of s-SHIP. However, analysis of s-SHIP expression
in primitive cell types or BM cells has not been demonstrated for this SHIP KO
model. To date, there does not exist an s-SHIP-/- model, which maintains WT
levels of full length SHIP, therefore it will be difficult to truly assess the role of sSHIP in stem cell biology until such a mouse model is developed.

In the

meantime, studies in ES cells using RNA interference techniques to target sSHIP expression will be useful in understanding the contribution of this protein in
the control of self-renewal and differentiation in pluripotent stem cells.

Most

importantly, more studies are needed to completely define the relationship
between s-SHIP, Grb2, and gp130 and their combined role in ES cell function.
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Materials and methods
Propagation of mES Cells
For our studies, we used TL1 strain mES cells, which were a kind gift from
Patricia A. Labosky, University of Pennsylvania, Philadelphia, Pennsylvania,
USA.

mES cells were first thawed on MEF cells and then transferred and

passaged on gelatin-coated dishes. Petri dishes (100mm plates, Nunc, Fisher
Scientific Inc. Suwanee, GA) were covered with 0.1% gelatin in ultrapure water
(Chemicon International/Specialty Media, Phillipsburg, NJ, USA) for at least 30
minutes. The extra gelatin was then removed. Cells were cultured in KO DMEM
media (Gibco BRL/Invitrogen), 15% ES cell qualified FBS (Invitrogen/Gibco
BRL), 2 mM L-Alanyl-L-Glutamine (ATCC, Manassas, VA, USA), 0.1 mM Nonessential amino acids (Gibco BRL/Invitrogen), 0.1 mM β-mercaptoethanol (β-ME)
(Sigma-Aldrich) with 1000 U/ml LIF (Chemicon International). ES cells were split
every other day using a 0.05% trypsin-EDTA treatment for 3-5 minutes.

Preparation of mES Cell Lysates for Biochemical Analysis

ES cells were grown in the presence of 1000 U/ml LIF. In preparation for
cell lysis, ES cells cell culture dish was placed on ice, the culture media was then
removed and the cells were washed twice with PBS containing 1 mM sodium
pervanadate (NaVO3).

ES cells were then lysed with modified RIPA buffer

(Upstate) containing 1 mM NaVO3 and protease inhibitor (Sigma-Aldrich). Lysis
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was performed at 4oC for 45 to 60 minutes.

Protein concentration was

established using the BCA protein assay kit (Pierce Biotechnology Inc.).

Nested Reverse-Transcription Polymerase Chain Reaction Assay for Detection
of s-SHIP Expression

Murine BM cells were isolated as mentioned previously.

RNA was

isolated from 1x106 WT and SHIP-/- BM cells following the protocol for the
RNAqueous-4PCR kit (Ambion).

RT-PCR was performed using MultiScribe

reverse transcriptase (Applied Biosystems) protocol. Briefly, 5xRT-PCR buffer (4
μl), 25 mM MgCl2 (2 μl), 10 mM dNTP (2 μl), RNase inhibitor (0.5 μl), 100 mM
DTT (2 μl) and random hexamers (0.5 μl) were mixed with RNase free water (up
to 20 μl) and RNA isolated from tested samples (equivalent of 1x104 cells).
MultiScribe RTase enzyme, 0.3 μl, was then added to the reaction, for a total
volume of 20 μl. The RT reaction was performed in a Px2 thermal cycler PCR
machine (Thermo Electron Corporation, Waltham, MA) using the following
program: 10 minutes at 25oC and then 12 minutes at 42oC. The RT products
were placed at 4oC for 1-2 hours. Ten μl of the RT reaction product was then
used for PCR amplification using a forward primer specific for the s-SHIP SSR
region and a reverse primer specific for a region approximately 460 bp
downstream of the s-SHIP SSR region.49

Briefly, cDNA (10 μl), RNase free

water (25 μl), 5x Amplitaq buffer (8 μl), 25 mM MgCl2 (2.5 μl), 10nM dNTP (3 μl),
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20 μM s-ship forward (1-25) and reverse (459-478) primers (0.5 μl each) and 0.5
μl of AmpliTaq (Applied Biosystems) were mixed prior to PCR amplification.
Amplification was performed in a Px2 thermal cycler PCR machine using the
following program: 10 minutes denaturation at 95oC followed by 43 cycles of 25
seconds at 94oC and 1 minute at 55oC, with a final extension phase at 72oC for 7
minutes. Twenty μl of the PCR reaction was then placed in a second PCR using
the same conditions, except that the primers were internal to the first round
amplification primers and targeted the s-SHIP nucleotides 21-41 (forward
primer), within the SSR region, and 463-478 (reverse primer). All primers were
obtained from Integrated DNA Technologies Inc. (Coralville, IA, USA).

The

expected PCR product for the s-ship nested PCR product is 442 base pairs,
which coincides with the product seen on a 1.2% agarose gel. Primers used for
s-SHIP nested PCR: Initial amplification: forward(1-25), 5’-gtt ccc act agt tgt tga
act tta c-3’ and reverse(478-459), 5’-tct cct tct ccg tct cca cc-3’; secondary
amplification: forward(21-41), 5’-ttt acc ttg aac ctc tgc tcc-3’ and reverse(463439) 5’-cca cca aaa tca cca act tgt tta g-3’.

Western blot antibodies and techniques

The Western blots apparatus consisted of the Novex X-cell II system with
Bis-Tris gel system (Novex/Invitrogen).

Typically 4 to 12% gels were used

(Novex/Invitrogen). Gels were run at RT for 2 hours at 150 Volts. Multi-Mark or
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BenchMark (Novex/Invitrogen) protein ladders were used to correlate molecular
weight of target proteins.

Proteins were electrophoretically transferred to

nitrocellulose membranes (Millipore, Billerica, MA, USA) for immunoblotting. The
blots were initially washed twice for 2 minutes in a solution of PBS 0.05% Tween
(PBS-T), then blocked for 1 hour at RT in 5% NFM in PBS with 0.05% Tween
(5% NFM/PBS-T). The blots were washed 3 x 5 minutes in PBS-T and then
incubated overnight at 4oC in anti-SHIP monoclonal antibody solution of P2C6
antibody (a kind gift from Dr. Larry Rohrschneider) at a concentration of 1:1000,
or the P1C1 monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) at a concentration of 1 μg/ml in 5%NFM/PBS-T. The following day, blots
were washed at least three times for 10 minutes and incubated with anti-mouseHRP conjugated antibody (Pierce Biotechnology Inc.) at concentration 1:80,000
for 2 hours at RT. The blot was then washed four times 5 minutes in PBS-T and
exposed with SuperSignal West Femto for 5 minutes (Pierce Biotechnology Inc.).

Cell stimulation
ES-TL1 cells were split into 4 different 100-mm TC plates and grown
overnight at 37oC in ES media supplemented with 1000 U/ml LIF to approximate
80% confluence. LIF-supplemented media was removed, cells were washed
twice with PBS, media without LIF was added, and cells were incubated for 5
hours. Cells were washed once with PBS and twice with Hanks balanced salt
solution (HBSS, Mediatech). Then they were pre-incubated in HBSS at 37oC for
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10 minutes. Cells were stimulated by the addition of HBSS containing 2000 U/ml
LIF and by incubation at 37oC for either 2, 5, or 10 minutes. A control ES plate (0
minute) containing HBSS without LIF was incubated at 37oC in parallel for 10
minutes. Stimulations were stopped by the removal of buffer and the addition of
10 ml ice-cold PBS/1 mM Na3VO4. PBS/Na3VO4 was removed, and 1mL ice-cold
modified RIPA buffer was added immediately. Cells were scraped, and cell
lysates were processed as described above. A20 cells were grown in RPMI and
were washed once with PBS and twice with HBSS. Then 2×107 cells were placed
in separate 15-mL conicals and were pre-incubated in HBSS at 37oC for 10
minutes. Cells were spun down, and HBSS was removed. After that, cells were
stimulated with 1 ml HBSS containing 20 μg/ml goat anti-mouse IgG (Southern
Biotechnology Associates, Birmingham, AL) and were incubated at 37oC for 5
minutes. Control A20 cells (0 minute) containing HBSS without anti-mouse IgG
were incubated in parallel. Stimulations were stopped by placing the conicals on
ice and adding 2 ml ice-cold PBS/Na3VO4. Cells were pelleted, supernatant was
removed, and 1 ml ice-cold modified RIPA buffer was added. One mg in 1 ml of
buffer was used for subsequent immunoprecipitation experiments.

Western blot analysis of gp130 immunoprecipitates

Equivalent amounts of protein lysate were first pre-cleared twice with 0.25
μg of appropriate nonspecific IgG isotype control followed by 50 μl of appropriate
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50% agarose bead slurry (Protein A or G) (Upstate). The beads had previously
been washed three times in cold PBS. They were then resuspended in PBS
containing 1mM NaVO3 to obtain a 50% slurry. The pre-cleared lysates were
then exposed to specific polyclonal antibodies against gp130 (M-20) (Santa Cruz
Biotechnology) and Grb2 (Santa Cruz Biotechnology) for 3 hours at 4oC on a
rotator. When peptide blocked antibodies were used for immunoprecipitation,
gp130 and Grb2 antibodies were incubated with their respective blocking
peptides (Santa Cruz Biotechnology) for at least 1 hour on a rotator at 4ºC prior
to being used for immunoprecipitation.

Once incubation with antibody was

completed, 50 μl of Protein A or G agarose beads 50% slurry was then added to
the immunoprecipitates and put on a rotator overnight at 4oC. The following day,
the supernatant was removed and beads were washed four times with FROP
buffer (150 mM NaCl, 5 mM CHAPS, 50 mM Tris pH 8). LDS sample buffer with
reducer (Novex/Invitrogen) was then added to the beads, and the bead/buffer
mixture was heated at 100oC for 5 minutes. Western blot analysis was then
performed as described above.
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FINAL DISCUSSION

One might be surprised to notice that through out this dissertation, SHIP is
given multiple roles. For example, in HSC we attributed to SHIP the ability to
impact proliferation, survival, homing and retention to the BM. In addition, a
similar scenario was observed when we studied the role of SHIP in MKP.
However, when we truly look at each of the signaling pathways that can be
influenced by SHIP, each of them can be linked to a function attributed to SHIP.
This protein can control proliferation through the regulation of the MAPK by
sequestration of Shc.1 Alternatively, it can contribute in the negative regulation of
the Akt signaling pathway, which promotes cell survival and proliferation.61
Furthermore, SHIP was shown to negatively control myeloid progenitor cell
response to SDF-1, SHIP-/- myeloid progenitors being more responsive to SDF-1
stimulation than WT.152 Additionally, SHIP by being a major regulator of the PI3K
downstream effector pathway can impact hematopoietic cell response to diverse
cytokines. Interestingly, PI3K is also known to bind to focal adhesion kinase
(FAK),375 and in this pathway, PI3K activation leads to the production of PI(3,4,5)P3
which contributes to the control of cell motility by FAK.

Thus, SHIP could

contribute to the negative regulation of this pathway. Moreover, we observed
that SHIP appears to contribute to the shaping of the NK cell receptor repertoire.
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Our results suggest that SHIP regulates the NK cell receptor repertoire diversity
through promotion of survival of certain NK cell subset. However, we can not
exclude that SHIP could also participate in NK cell receptors transcription
regulation.

SHIP has been shown to influence I-κB activity, which regulates

NFκB function.

Most interestingly, NF-κB was shown to contribute to the

regulation of Ly49 receptor expression.331

More studies are needed to truly

define the role of SHIP in all these different pathways.

Furthermore, it is

necessary to establish which isoform or isoforms are involved in each of these
pathways in every cell type, since each isoform contains different combination of
functional domains.

After studying SHIP for 5 years, it is clear to me that it plays different roles
depending on the hematopoietic cells type, the cell context, and the cell
environment. Another testament to its variegated role in the control of cellular
function is the fact that SHIP has several isoforms and that each of them appear
to be expressed differently in diverse cell types.4,49,53

In theory, every SHIP

isoform still contains a functional 5’ inositol phosphatase enzymatic domain.
Phosphatidylinositols are used to transmit signal from different external stimuli to
activate cellular response that can lead to calcium mobilization, protein
phosphorylation, cell proliferation, activation and survival. Therefore, SHIP has
the potential to influence each of these pathways. However, the fact that these
SHIP isoforms lack some of the protein interaction domain, will modify the

151

cellular context in which these isoforms will be recruited to the membrane or site
of action. For example s-SHIP, which has no SH2 domain, will be restricted in its
ability to interact with phosphorylated tyrosine.

Another isoform, SHIPΔ183,

lacks a region between the two NPXY leading to a disruption of a consensus
sequence necessary for the binding of PI3K p85 subunit.

Interestingly, the

different isoform appear to be differentially expressed by diverse cell type. This
can provide the cell with an isoform that will correspond to the need of that
particular cell. For example, ES cells express only s-SHIP and not full length
SHIP, while HSC express both isoforms.49 It was also shown that untreated
human BM cells express a 110kDa isoform, but when the same cells were
treated in vitro with IL-3 and M-CSF to promote differentiation towards the
myeloid lineage, full length SHIP was observed.53

Noteworthy are the observations linking SHIP-deficiency to premature
aging. For example SHIP-deficient mice suffer from osteoporosis due to hyperresponsive osteoclasts.101 Furthermore, SHIP-/- BM have an increased number
of HSC, which are not as efficient as WT at reconstituting an irradiated host.156,246
Moreover, the SHIP-/- hematopoietic system is skewed towards myeloid cell
differentiation.95 All of these are characteristics that have been associated with
aging.376-383

It would be interesting to address the hypothesis that SHIP

deficiency causes accelerated aging in mice.
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Although SHIP is known to influence many signaling pathways in different
cell types, its deficiency is not associated with many diseases. SHIP appears to
be absent in some forms of acute leukemias.384 It was also associated with
myeloproliferative disorder95 and with osteoporosis.101 Nevertheless, the study of
the germline SHIP-/- mouse model did not allow confirming that SHIP mutation
might be associated with any other disease, yet. It will be important to study the
conditional knock-out system to establish more precisely if SHIP deletion or
mutation during adulthood might participate in the development of cancers,
allergic, auto-immune or inflammatory condition.
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